1. Introduction {#sec1}
===============

The spread of antimalarial resistance is hampering malaria control and elimination efforts globally ([@bib1], [@bib63]). Poor quality antimalarials can be categorised into three main groups: falsified; substandard; and degraded ([@bib66]). Each of these can be a source of subtherapeutic doses of the active ingredient(s), which promote the emergence and transmission of drug resistant parasites through selection pressures ([@bib5], [@bib46], [@bib62]). Falsified antimalarials are those that are fraudulently made and typically contain an incorrect amount of active ingredient, incorrect active ingredient, toxic substances, or no active ingredient. Substandard antimalarials are those made by licenced companies but use poor manufacturing practices. Degraded antimalarials degrade from their initial quality due to inadequate storage conditions, such as excessive heat. In addition, within poor quality antimalarials, we include those that are not recommended in the World Health Organization (WHO) guidelines.

Approximately 30% of antimalarial medicines in Africa and Asia are considered to be falsified or substandard ([@bib1], [@bib39]). The outcome for those receiving poor quality antimalarials ranges from prolonged malaria symptoms, unexpected side effects, financial strain due to loss of income or healthcare costs, or even death ([@bib1], [@bib38], [@bib51]). In Kenya, prior to 2004, sulfadoxine-pyrimethamine (SP) had been recommended as first-line for treatment of malaria. Due to increasing resistance to SP, stemming from mutations in the *P. falciparum* dihydrofolate reductase (DHFR) gene, which affects pyrimethamine, and the dihydropteroate synthase (DHPS) gene, which affects sulfadoxine, Kenya adopted artemether-lumefantrine (AL) as its first-line treatment in 2004. In 2001, WHO recommended the use of artemisinin-based combination therapies (ACTs) as first-line policy ([@bib64]). In December 2007, a report was produced surveying the antimalarial medicines available in Kenya and their quality. The researchers identified a wide range of products on the market, the majority of which were not in-line with the new national guidelines, and a high proportion were either un-registered or of low quality ([@bib36]).

The effect of antimalarial use on the transmission of resistance has been modelled previously ([@bib18], [@bib25], [@bib26], [@bib31], [@bib52]). Notably, the models currently available do not take into account the quality or percentage of antimalarial active ingredient and its effect on transmission. As summarised by [@bib26], part of the issue preventing these resistance transmission models from being developed and used is a lack of complete, comprehensive datasets for key parameters. Since their model was published, work has been carried out to look at the effect of drug quality on resistance within mice ([@bib19], [@bib22]) and the effect of treatment in humans with SP-resistant infections ([@bib4], [@bib5], [@bib34]).

Here we develop a new model to explore the impact of antimalarial quality, defined as poor quality SP, as defined above, and good quality AL, on the transmission of SP antimalarial resistance in *Plasmodium falciparum*. To assist in more realistic parameterisation of the model, we applied the model to Kenya in 2006, rather than Kenya being a focus for actual predictions. The model assumes that low to moderate SP-resistance conferred by mutations in the DHFR gene, the target of pyrimethamine, has already been established within both human and mosquito populations.

2. Materials and methods {#sec2}
========================

2.1. Model structure {#sec2.1}
--------------------

We developed a deterministic compartmental model to explore the impact of antimalarial quality on the transmission of *P. falciparum* SP resistance ([Fig. 1](#fig1){ref-type="fig"}). The model quantifies the transmission dynamics of SP-sensitive (denoted $w$) and SP-resistant (denoted $r$) *P. falciparum* between female *Anopheles* mosquitoes and humans. The human-mosquito system is modelled using ordinary differential equations (ODEs) (Eq. [(A1)](#fd1){ref-type="disp-formula"}, [Appendix A1](#appsec1.1){ref-type="sec"}). Humans may be infected by SP-sensitive strains $\left( w \right)$, SP-resistant strains $\left( r \right)$, or both $\left( {wr} \right)$. Resistance to SP was defined as the presence of DHFR-51 and DHFR-108 pyrimethamine resistance-conferring mutations ([@bib34]), used as proxy for all low to moderate SP-resistant conferring mutations in *P. falciparum* ([@bib48]). At baseline, the percentage of humans and mosquitoes with SP-resistant infections was set to 42% ([@bib27], [@bib47]) and mixed infections was set to 8% ([@bib27]).Fig. 1A summary of the structure of the mathematical model showing the movement between compartments of SP-sensitive and SP-resistant *Plasmodium falciparum* in humans and female *Anopheles* mosquitoes (blue solid line). The transmission of gametocytes (infected human to susceptible mosquito) and sporozoites (infected mosquito to susceptible human) during a blood meal, is depicted by the red dotted line for SP-sensitive, and a dark green dotted line for SP-resistant.Fig. 1

Humans free of *P. falciparum* were classified as susceptible and denoted by $S\left( H \right)$. When transmission of sporozoites occurs from female *An.* mosquitoes to humans during a blood meal, the human moves into the exposed class ($\left. E\left( H \right)_{i} \right)$ at the rate $\beta_{H,i}$. The script $i$ indicates a SP-sensitive ($i$ is $w$) or SP-resistant ($i$ is $r$) *P. falciparum* infection. Due to the difference in the latent periods for asexual *P. falciparum* and gametocytes, it is assumed that antimalarial treatment is sought while in the exposed class to treat malaria symptoms as part of the asexual lifecycle ([@bib42]). There are four types of treatment available, each used as a proxy for 'good quality' or 'poor quality' treatments. Infected humans receive each treatment type with probability $\theta_{d}$, where the subscript $d$ is $q$ for a full dose of AL (good quality); $m$ for a full-dose of SP monotherapy (poor quality); $p$ for a half-dose SP monotherapy (poor quality); and $n$ for no treatment, either through no antimalarial compound within the medicine sought or choosing not to seek treatment (poor quality). Following the gametocyte latency period, those in the exposed class move into the infectious class at rate $\sigma_{H\ }$, which is assumed to be equal for both SP-sensitive and SP-resistant infections. The length of infectiousness and probability of transmission of gametocytes from infected humans to mosquitoes are specified for each strain $\left( {i = w,r\ or\ wr} \right)$ and treatment $\left( {d = q,m,p\ or\ n} \right)$ combination. The recovery rate is defined by $\gamma_{i,d}$. Natural immunity is gained at rate $\gamma_{R}$, among those who do not receive treatment ([@bib7]), and lost at rate $\rho$. The protective nature and rates for gaining and losing natural immunity are also assumed to be independent of *P. falciparum* infection type.

Female *Anopheles* mosquitoes may be susceptible $\left( S\left( M \right) \right)$, exposed $\left( {E\left( M \right)_{i}} \right)$, or infected $\left( {I\left( M \right)_{i}} \right)$. Movement from susceptible to an exposed class, after the transmission of *P. falciparum* during a blood meal, occurs at rate $\beta_{M,i}$; where $i$ is $w$ for SP-sensitive parasites or $r$ for SP-resistant *P. falciparum*. The rate of transmission is defined as the product of the daily mosquito biting rate $\left( c \right)$ and the probability of transmission given parasite strain and drug treatment received by the human (${\widetilde{Z}}_{w}$ or ${\widetilde{Z}}_{r}$). We assume that *An.* mosquitoes can only be infected by one strain of *P. falciparum* gametocytes (i.e., no mixed infections), and in the occurrence that a susceptible mosquito feeds on a human host with a mixed infection, the probability of the SP-sensitive strain being selected over the SP-resistant strain $\left( P_{w} \right)$ and proceeding through the mosquito\'s midgut and onto the salivary gland, is set at 0.6, assigning a relatively small fitness cost to resistance ([Appendix D1](#appsec4.1){ref-type="sec"}). Following the latent period, the mosquito enters the infectious class $\left( {I\left( M \right)_{i}} \right)$ at rate $\sigma_{M}$, and it is assumed that they do not recover from their infection due to their short lifespans ([@bib32]). The parameters used in the model are defined in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}. Additional parameters, including details on the calculations of mosquito and human demographic turnover rates can be found in [Appendices B--E](#appsec2){ref-type="sec"}. The impact of SP on the level of gametocytes in humans has been extensively researched ([@bib4], [@bib5], [@bib7], [@bib34]). We calculated an estimate for the length of gametocyte carriage and the probability of transmission when treated with a full dose pyrimethamine, half dose (using 50% or 37.5% of a full dose) of pyrimethamine, or no treatment ([@bib20], [@bib22], [@bib19]), and then calibrated these scenarios against human SP monotherapy studies ([@bib4], [@bib5], [@bib34]) ([C2](#appsec3.2){ref-type="sec"}, [C3](#appsec3.3){ref-type="sec"}).Table 1**Human Parameters**. A summary of the model parameters used to calculate the rates of change in human movement (daily) between model compartments, including: parameter definitions, symbols, parameter values used in the baseline model, and literature references or the section of the Appendices where the parameters are defined.Table 1Parameter descriptionSymbolValueReferenceHuman population size (initial)$N_{H}$$1$Updated per iterationBirth rate$\text{Ω}_{H}$1.1349 × 10^−4^[Appendix B1](#appsec2.1){ref-type="sec"}Rate of humans becoming exposed to SP-sensitive sporozoites$\beta_{H,w}$0.0810[Appendix B2](#appsec2.2){ref-type="sec"}Rate of humans becoming exposed to SP-resistant sporozoites$\beta_{H,r}$0.0810[Appendix B2](#appsec2.2){ref-type="sec"}Rate of humans becoming infectious (gametocytes)$\sigma_{H\ }$0.0556[Appendix B3](#appsec2.3){ref-type="sec"}Receiving AL (proportion, at baseline)$\theta_{q}$0.70Assumed, [Appendix C1](#appsec3.1){ref-type="sec"}Receiving full-dose SP monotherapy (proportion, at baseline)$\theta_{m}$0.07[@bib15]Receiving full-dose SP monotherapy (proportion, at baseline)$\theta_{p}$0.03[@bib37], [@bib38], [@bib51]Receiving no treatment (proportion, at baseline)$\theta_{n}$0.20[@bib13]Rate of human recovery from SP-sensitive *P. falciparum* having received AL$\gamma_{w,q}$0.1667[Appendix B4](#appsec2.4){ref-type="sec"}Rate of human recovery from SP-sensitive *P. falciparum* having received full-dose SP monotherapy$\gamma_{w,m}$0.0588[Appendix B4](#appsec2.4){ref-type="sec"}Rate of human recovery from SP-sensitive *P. falciparum* having received half-dose SP monotherapy$\gamma_{w,p}$0.0476[Appendix B4](#appsec2.4){ref-type="sec"}Rate of human recovery from SP-resistant *P. falciparum* having received AL$\gamma_{r,q}$0.1667[Appendix B4](#appsec2.4){ref-type="sec"}Rate of human recovery from SP- resistant *P. falciparum* having received full-dose SP monotherapy$\gamma_{r,m}$0.0096[Appendix B4](#appsec2.4){ref-type="sec"}Rate of human recovery from SP- resistant *P. falciparum* having received half-dose SP monotherapy$\gamma_{r,p}$0.0096[Appendix B4](#appsec2.4){ref-type="sec"}Rate of human recovery from mixed *P. falciparum* infection having received AL$\gamma_{wr,q}$0.1667[Appendix B4](#appsec2.4){ref-type="sec"}Rate of human recovery from mixed *P. falciparum* infection having received full-dose SP monotherapy$\gamma_{wr,m}$0.0096[Appendix B4](#appsec2.4){ref-type="sec"}Rate of human recovery from mixed *P. falciparum* infection having received half-dose SP monotherapy$\gamma_{wr,p}$0.0119[Appendix B4](#appsec2.4){ref-type="sec"}Rate of recovery having received no treatment$\gamma_{n}$0.0149[Appendix B4](#appsec2.4){ref-type="sec"}Overall transmission of SP-sensitive gametocytes (probability)${\widetilde{\text{Ζ}}}_{w}$0.1459[Appendix D2](#appsec4.2){ref-type="sec"}Overall transmission of SP-resistant gametocytes (probability)${\widetilde{\text{Ζ}}}_{r}$0.1410[Appendix D2](#appsec4.2){ref-type="sec"}Rate of acquired immunity$\gamma_{R}$6.0864 × 10^−4^[Appendix B5](#appsec2.5){ref-type="sec"}Rate of loss of acquired immunity$\rho$0.0027[@bib28]Rate of malarial mortality in humans$\mu_{I}$8.2880 × 10^−4^[Appendix B6](#appsec2.6){ref-type="sec"}Rate of "other" mortality in humans$\mu_{O}$3.1779 × 10^−5^[Appendix B6](#appsec2.6){ref-type="sec"}Table 2**Mosquito Parameters**. A summary of the model parameters used to calculate the rates of change of movement (daily) of female *An.* mosquitoes between model compartments, including: parameter definitions, symbols, parameter values used in the baseline model, and literature references or the section of the Appendices where the parameters are defined.Table 2Parameter descriptionSymbolValueReferenceRatio of *An.* mosquito to human population (initial)$N_{M}$0.87Updated per iterationRate female *An.* mosquitoes reach adulthood$\text{Ω}_{M}$0.0280[@bib12], [@bib28]Biting rate of female *An.* Mosquitoes$c$0.4050[@bib2], [@bib32]Rate of mosquitoes becoming exposed to SP-sensitive gametocytes$\beta_{M,w}$0.0591[Appendix E1](#appsec5.1){ref-type="sec"}Rate of mosquitoes becoming exposed to SP-resistant gametocytes$\beta_{M,r}$0.0571[Appendix E1](#appsec5.1){ref-type="sec"}Rate of mosquitoes becoming infectious (sporozoites at salivary gland)$\sigma_{M}$0.2000[Appendix E2](#appsec5.2){ref-type="sec"}Rate of mortality of female *An.* mosquitoes$\mu_{M}$0.0280[@bib32], [Appendix E3](#appsec5.3){ref-type="sec"}

The model simulations were run at the 2006 baseline level for all parameters, with the initial conditions ([Appendix A2](#appsec1.2){ref-type="sec"}) chosen to match surveillance data observed in Kenya in 2006. The system was solved for 1 year (2006), and the results analysed. All analysis were carried out in Mathworks Matlab 2012a, using the ODE15s solver.

2.2. Gametocyte carriage and infectiousness {#sec2.2}
-------------------------------------------

The parameter values for the duration of gametocyte carriage and the probability a mosquito takes up a mature (infectious) gametocyte during a blood meal, given the infection-type and treatment received by the patient, utilised a combination of data from mice malaria studies for pyrimethamine ([@bib20], [@bib22], [@bib19]) and human SP studies ([@bib4], [@bib5], [@bib34]). Pyrimethamine (not in combination with sulfadoxine) mice studies were used to inform parameterisation due to the availability of data on pyrimethamine, with no such data was available on SP. This method is described in [C2](#appsec3.2){ref-type="sec"}, [C3](#appsec3.3){ref-type="sec"}.

The expected duration of gametocyte carriage, given treatment scenarios, were calculated and compared to the 2006 baseline treatment level (70% AL use (assumed, [Appendix C1](#appsec3.1){ref-type="sec"}), 7% full-dose SP monotherapy ([@bib15]), 3% half-dose SP monotherapy ([@bib37], [@bib38], [@bib51]), and 20% no treatment ([@bib13])), in [Fig. 2](#fig2){ref-type="fig"}A and [Table 3](#tbl3){ref-type="table"}. An increase in the use of full-dose or half-dose SP monotherapy use, or no treatment by 1% (with a corresponding 1% decrease in AL use), resulted in an increase in the duration of gametocyte carriage from baseline (16.1 days) of 2½ hour, 3 h and 16 h, respectively. However, exclusive use of either full-dose or half-dose SP (all other treatments set to 0%), results in the duration decreasing from baseline (3.3 days and 1.6 days, respectively); whereas increasing when no treatment is exclusively used by 50.9 days; indicating no treatment has a large impact on carriage. In contrast, as the percentage of AL treatment increases, a decrease in the average duration of gametocyte carriage is observed (2 h per 1% increase), down to an eventual duration of 2 days when used exclusively.Fig. 2(A) The impact of antimalarial quality on the average duration of gametocyte carriage in humans. (B--C) The impact of antimalarial quality on the infectiousness of humans to mosquitoes during a blood meal (probability), of (B) SP-sensitive and (C) SP-resistant gametocytes. Changes in the percentage use of full-dose SP monotherapy ($\theta_{m}$, orange line) were adjusted for the use of 3% half-dose SP monotherapy $\left( \theta_{p} \right)$, 20% receiving no treatment $\left( \theta_{n} \right)$ and the remainder AL treatment $\left( \theta_{q} \right)$. Likewise, changes in half-dose SP monotherapy use (*θ~p~*, purple line) were adjusted for $\theta_{m} = 7\%,\ \theta_{n} = 20\%$ and $\theta_{q} =$ remainder; changes in those receiving no treatment (*θ~n~*, blue line) were adjusted for $\theta_{m} = 7\%,\ \theta_{p} = 3\%$ and $\theta_{q} =$ remainder; and changes in AL use (*θ~q~*, green line) were adjusted for $\theta_{p} = 3\%,\ \theta_{n} = 20\%$ and $\theta_{m} =$ remainder. The 2006 model baseline (black line) corresponds to $\theta_{q} = 70\%,\ \theta_{m} = 7\%,\ \theta_{p} = 3\%$ and $\theta_{n} = 20\%$.Fig. 2Table 3The impact of changes in the percentage use of treatments (after 365 days), with percentage change, when compared to 2006 model baseline for: the average duration of gametocyte carriage; and the probability of mosquitoes taking up infectious gametocytes. The 2006 model baseline treatment use was set to 70% AL treatment $\left( \theta_{q} \right)$, 7% full-dose SP monotherapy $\left( \theta_{m} \right)$, 3% half-dose SP monotherapy $\left( \theta_{p} \right)$ and 20% no treatment $\left( \theta_{n} \right)$. Changes in the percentage use of full-dose SP monotherapy $\left( \theta_{m} \right)$ were adjusted for $\theta_{p} = 3\%,\ \theta_{n} = 20\%$ and $\theta_{q}$ = remainder; changes in the use of half-dose SP monotherapy use (*θ~p~*) were adjusted for $\theta_{m} = 7\%,\ \theta_{n} = 20\%$ and $\theta_{q} =$ remainder; changes in those receiving no treatment (*θ~n~*) were adjusted for $\theta_{m} = 7\%,\ \theta_{p} = 3\%$ and $\theta_{q} =$ remainder; and changes in AL use (*θ~q~*) were adjusted for $\theta_{p} = 3\%,\ \theta_{n} = 20\%$ and $\theta_{m} =$ remainder. For exclusive use of a treatment (100% use), all other treatments were set to 0%.Table 3Drug Use ScenariosDuration gametocyte carriageProbability infectious gametocytesSP-sensitiveSP-resistant2006 model baseline16.1 days0.14590.1410+1% full-dose SP use+2½ hours (0.6%)+0.0016 (1.1%)+0.0035 (2.5%)+1% half-dose SP use+3 hours (0.8%)+0.0008 (0.5%)+0.0002 (0.1%)+1% no treatment+16 hours (4.2%)+0.0024 (1.6%)+0.0021 (1.5%)+1% AL use− 2 hours (0.5%)− 0.0015 (1.0%)− 0.0034 (2.4%)100% full-dose SP use− 3.3 days (20.4%)+0.0951 (65.2%)+0.2830 (200.7%)100% half-dose SP use− 1.6 days (10.2%)+0.0178 (12.2%)−0.0498 (35.3%)100% no treatment+50.9 days (316.1%)+0.1741 (119.3%)+0.1390 (98.6%)100% AL use−14.1 days (87.6%)−0.0600 (41.1%)−0.0658 (46.7%)

The calculated probability of mosquitoes taking up infectious gametocytes during a blood meal also increased in response to greater use of full- and half-dose SP monotherapy, and no treatment ([Fig. 2](#fig2){ref-type="fig"}B--C, [Table 3](#tbl3){ref-type="table"}). In settings where SP resistance is already firmly established, a 1% increase in full-dose SP monotherapy resulted in a larger percentage increase in SP-resistant infectiousness, than sensitive infectiousness (2.5% v 1.1%). This is further highlighted under the scenario of exclusive use of full-dose SP, where results indicate a 200.7% increase in the probability of mosquitoes taking up SP-resistant *P. falciparum*, compared to a 65.2% increase in SP-sensitive *P. falciparum*. In contrast, 1% increases in half-dose SP or no treatment use had a greater percentage increase in the probability of mosquitoes taking up SP-sensitive *P. falciparum* (0.5% and 1.6%, respectively) compared to SP-resistant *P. falciparum* (0.1% and 1.5%, respectively). However, when used exclusively, half-dose SP had the greatest percentage increase in SP-resistant *P. falciparum* compared to SP-sensitive (35.3% v 12.2%); with exclusive use of no treatment resulting in a similarly large percentage increase for both (98.6% and 119.3%, respectively). Changes in the use of AL resulted in a greater decrease in the probability of SP-resistant *P. falciparum* being taken up by mosquitoes, compared to SP-sensitive *P. falciparum* (2.4% v 1.0%, for 1% increase; and 46.7% v 41.1%, when exclusively used).

2.3. Measuring the effect on transmission {#sec2.3}
-----------------------------------------

The main outcome of interest is the impact of antimalarial quality on the total proportion of SP-resistant infections (resistant and mixed infections) in the human population ($\varnothing$, Eq. [(1)](#fd1){ref-type="disp-formula"}):$$\varnothing = \frac{\sum_{\text{X}}\text{X}\left( \text{H} \right)_{w}\text{I}\left( \text{H} \right)_{r}}{\sum_{\text{X}}\text{I}\left( \text{H} \right)_{w}\text{X}\left( \text{H} \right)_{r} + \sum_{\text{X}}\text{X}\left( \text{H} \right)_{w}\text{I}\left( \text{H} \right)_{r} - \text{I}\left( \text{H} \right)_{w}\text{I}\left( \text{H} \right)_{r}}$$

Here $\text{X}\left( \text{H} \right)$ denotes the human classes (excluding acquired immunity), where the subscript $w$ and $r$ once again denote SP-sensitive and SP-resistant *P. falciparum*, respectively.

In addition to the proportion of SP-resistant infections, we also measured the expected number of malaria cases in humans.

2.4. Model accuracy {#sec2.4}
-------------------

To validate our results, we performed a sensitivity analysis, and compared baseline model predictions against estimates found in the literature. A one-way sensitivity analysis was carried out, where each parameter was individually changed to the minimum and maximum value in its defined parameter range, and the change in the total proportion of SP-resistant infections in the human population was calculated. Parameters that inferred a change of greater than $\pm 10\%$ were considered to be significant during the sensitivity analysis.

3. Results {#sec3}
==========

To quantify the impact of antimalarial quality on the transmission of SP resistance in *P. falciparum*, we varied the amount of good and poor quality antimalarial use in the population. Any change in antimalarial use that assists the survival and propagation of antimalarial resistance within human and mosquito populations highlights the need for better control and regulations of the use and availability of these medicines in order to offer safe and effective treatment.

3.1. Malaria cases (human) {#sec3.1}
--------------------------

At baseline, our model predicts 10,807,000 malaria cases in Kenya during 2006 ([Fig. 3](#fig3){ref-type="fig"}A, [Table 4](#tbl4){ref-type="table"}). An increase in the use of poor quality antimalarial use predicts a greater number of malaria cases, with the greatest increase observed under the scenario of full-dose SP being exclusively used (776.9%), followed by no treatment (773.6%) and the exclusive use of half-dose SP use (558.6%). This suggests that people may experience multiple malaria infections within one calendar year (population size 36,757,498 ([@bib60])). Under the exclusive use of AL, the model predicts that the number of malaria cases in Kenya for 2006 could have been 2,978,200 (a reduction of 72.5% from baseline). The proportion of malaria cases that contained SP-resistant *P. falciparum* reflects these increases under each scenario of SP use, where exclusive use of full-dose SP increases by 18.4% from baseline, and half-dose increases by 13.8% ([Fig. 3](#fig3){ref-type="fig"}B, [Table 4](#tbl4){ref-type="table"}). Decreases in the proportion of SP-resistant infections were observed when no treatment was used (−5.8%) and the exclusive use of AL (−1.8%).Fig. 3(A) The impact of antimalarial quality on the predicted number of human malaria cases in 2006. (B) The impact of antimalarial quality on the total proportion of SP-resistant infections in humans. Changes in the percentage use of full-dose SP monotherapy ($\theta_{m}$, orange line) were adjusted for the use of 3% half-dose SP monotherapy $\left( \theta_{p} \right)$, 20% receiving no treatment $\left( \theta_{n} \right)$, and the remainder AL treatment $\left( \theta_{q} \right)$. Likewise, changes in half-dose SP monotherapy use (*θ~p~*, purple line) were adjusted for $\theta_{m} = 7\%,\ \theta_{n} = 20\%$, and $\theta_{q} =$ remainder; changes in those receiving no treatment (*θ~n~*, blue line) were adjusted for $\theta_{m} = 7\%,\ \theta_{p} = 3\%$ and $\theta_{q} =$ remainder; and changes in AL use (*θ~q~*, green line) were adjusted for $\theta_{p} = 3\%,\ \theta_{n} = 20\%$, and $\theta_{m} =$ remainder. The 2006 model baseline (black line) corresponds to $\theta_{q} = 70\%,\ \theta_{m} = 7\%,\ \theta_{p} = 3\%$, and $\theta_{n} = 20\%$. Model simulations run for 365 days.Fig. 3Table 4The impact of changes in the percentage use of treatments (after 365 days) on the expected number of malaria cases in Kenya for 2006 and the proportion of resistant infections (percentage change), when compared to the 2006 model baseline. The 2006 model baseline treatment use was set to 70% AL treatment $\left( \theta_{q} \right)$, 7% full-dose SP monotherapy $\left( \theta_{m} \right)$, 3% half-dose SP monotherapy $\left( \theta_{p} \right)$, and 20% no treatment $\left( \theta_{n} \right)$; and for the exclusive use of a treatment (100% use), all other treatments were set to 0%.Table 4Drug Use ScenariosExpected malaria cases (2006)Proportion SP-resistant2006 model baseline10,807,0000.8404100% full-dose SP use+83,964,000 (776.9%)+0.1545 (18.4%)100% half-dose SP use+60,366,000 (558.6%)+0.1157 (13.8%)100% no treatment+83,608,000 (773.6%)−0.0491 (−5.8%)100% AL use−7,831,300 (−72.5%)−0.0148 (−1.8%)

3.2 Results validation {#sec3.2}
----------------------

Key 2006 baseline model output was compared to empirical estimates for the Kenyan population ([Table 5](#tbl5){ref-type="table"}), indicating our model predicted these outputs within an acceptable range. For the sensitivity analysis, parameters that inferred a change in the total proportion of SP-resistant infections in the human population of greater than $\pm 10\%$ were considered to be significant ([Table 6](#tbl6){ref-type="table"}). As seen with other malaria models ([@bib32]), our model was sensitive to mosquito parameters, such as the proportion of mosquitoes to humans, the daily rate female *An.* mosquitoes reach adulthood, and the probability of transmission of SP-sensitive and SP-resistant sporozoites during a blood meal. Additionally, the expected gametocyte clearances of SP-sensitive and SP-resistant gametocytes when treated with AL were found to significantly influence model outputs. The full sensitivity analysis is available in [Appendix F](#appsec6){ref-type="sec"}.Table 5**Results validation**. A comparison of the baseline model outcomes with literature estimates for 2006 and the published reference, including the percentage error in the 2006 model estimate, for: the rate of population growth; the proportion of each strain of *Plasmodium falciparum* malaria in humans; the number of *P. falciparum* cases of malaria in humans; and the human mortality (total and malaria-specific).Table 5Description2006 Model Outcome2006 Literature Value (Reference)Difference (%)Population growth, % (2006--2007)2.75592.7 ([@bib55])2Malaria cases10,857,0008,926,058 ([@bib64])22Deaths (all)500,980404,332 ([@bib55])24Malaria-specific deaths72,59274,970 ([@bib55], [@bib64])−3Proportion of SP-sensitive infections in humans $\left( w \right)$0.16250.05--0.5 ([@bib27])Within rangeProportion of SP-resistant infections in humans $\left( r \right)$0.83560.42--0.90 ([@bib27], [@bib47])Within rangeProportion of mixed infections in humans $\left( {wr} \right)$0.00190--0.53 ([@bib27])Within rangeTable 6**Sensitivity analysis summary**. Results for the sensitivity analysis, where parameter range (minimum and/or maximum) resulted in a $\pm 10\%$ change in the proportion of SP-resistant infections in humans. Full sensitivity analysis results are available in [Appendix F](#appsec6){ref-type="sec"}. ^A^ Largest value we could get a numerical solution for, actual literature range maximum value is 0.27.Table 6ParameterRange (literature range or ±10%)Percentage change (%)BaselineMinimumMaximumMinimumMaximumRatio of mosquito to human population (initial, humans = 1) $\left( N_{M} \right)$0.870.5400.32−20.55Rate female *An.* mosquitoes reach adulthood $\left( \text{Ω}_{M} \right)$0.0280.0200.1406 ^A^0.26−36.20SP-sensitive sporozoite transmission (probability) $\left( T_{w} \right)$0.20.20.50.00−86.98SP-resistant sporozoite transmission (probability) $\left( T_{r} \right)$0.20.20.50.0017.90SP-sensitive gametocyte clearance in humans treated with AL $\left( \varepsilon_{w,q} \right)$147289.20−13.61SP-resistant gametocyte clearance in humans treated with AL $\left( \varepsilon_{r,q} \right)$14728−15.528.65

4. Discussion {#sec4}
=============

Our model suggests that once SP resistance is widespread, as was the case in Kenya in 2006, an increase in poor quality antimalarial use (focusing on SP) results in an increase in: (i) the number of human malaria cases ([Fig. 3](#fig3){ref-type="fig"}A), and (ii) of these cases, an increase in the proportion of SP-resistant infections in humans (full- or half-dose SP used, [Fig. 3](#fig3){ref-type="fig"}B), when compared to good quality antimalarial use (AL). The predicted increase in malaria cases is of concern, where the scenario of full-dose SP being exclusively used (+776.9%), followed by no treatment (+773.6%) and the exclusive use of half-dose SP use (+558.6%), yield large increases; whereas the exclusive use of AL results in a marked decrease in the number of expected cases (−72.5%). The predicted increase in resistant-containing infections under SP drug pressure is supported by findings from Hastings ([@bib18]). Our findings suggest that a delay in *P. falciparum* clearance in humans, due to SP-resistance and/or inadequate antimalarial active ingredient, allows for prolonged transmission of SP-resistant gametocytes, hence ensuring their propagation throughout human and mosquito populations.

There are clear examples of substandard SP circulating in east Africa and elsewhere (see <http://www.wwarn.org/aqsurveyor/#0>). A common problem has been impaired drug dissolution due to poor manufacturing, despite having the correct amounts of SP in the tablet, which result in low blood SP drug levels ([@bib29], [@bib62]). The impacts described here for reduced dosage of SP will also apply to this situation of reduced bioavailability. In addition, systematic under-dosing of antimalarials, common in pregnancy and young children, has been shown to impact efficacy, with theoretical impacts of the selection of drug resistance ([@bib5], [@bib44]). In all these cases, the key variable will be the antimalarial levels parasites are exposed to, reflecting both antimalarial content and bioavailability.

The impact of antimalarial quality on mortality could not be explicitly explored as the model assumes that the proportion of malaria-specific mortality $\left( \mu_{I} \right)$ is proportional to the prevalence of malaria and hence driven by this relationship. This additionally acts to drive the overall mortality.

The accuracy of the model indicated larger percentage errors in the predicted malaria cases and malaria deaths for 2006 ([Table 5](#tbl5){ref-type="table"}). However, this simulated number of malaria cases is below the 15 million cases estimated to have occurred in Kenya in 2006 ([@bib64]), where under-reporting is considered a factor. This under-reporting is also assumed for malarial deaths, where there are discrepancies between the estimated (overall) deaths in Kenya in 2006 ([@bib56], [@bib64]) ([Appendix B6](#appsec2.6){ref-type="sec"}).

The parameterisation of the transmissibility and infectiousness of gametocytes under each treatment type utilised a combination of data from mice malaria studies for pyrimethamine ([@bib20], [@bib22], [@bib19]) and human SP studies ([@bib4], [@bib5], [@bib34]). The use of these calculated estimates introduces a margin of error; as well as the possible under-estimation of the transmissibility and infectiousness of those receiving a half-dose of SP ([Appendix C3.2](#appsec3.3.2){ref-type="sec"}). The impact of antimalarial quality on the duration of gametocyte carriage seems plausible, with the largest increase predicted from increases in those who receive no treatment. Increases in carriage duration were observed with increases in the percentage SP use, with half-dose SP monotherapy showing more marked increases in carriage duration than full-dose SP monotherapy. This may be explained by SP-sensitive infections being cleared more slowly following sub-therapeutic concentrations of antimalarial medicine, then when using full-dose SP, thereby providing a longer period for gametocytes to remain in circulation. Interestingly, this relationship was not observed when considering pyrimethamine-resistant gametocyte density in mice, despite peak density and carriage often being correlated ([@bib22]). The limitations in approximating these parameters further highlight the need for more data in this area, as well as other more currently utilised antimalarial drugs.

The model assumed that SP-resistance is conferred by mutations in the DHFR gene, omitting other possible mutations conferring sulfadoxine-resistance, or other mutations in the DHFR gene such as C59R or the high level resistance-conferring I15L mutation ([@bib43]). The selection of low to moderate SP resistance was due to the availability of data (or lack thereof), highlighting the need for further research in this area.

It must be noted that both symptomatic and asymptomatic infections ([@bib9]), as well as those with acquired immunity ([@bib24]), harbour gametocytes. The transmission potential of asymptomatic or acquired immune individuals were not included as a source of transmission, as they are outside of the scope of this study. Additionally, the model parameterised the mortality of mosquitoes irrespective of infection-status; did not allow mixed infections within the mosquito population; and a fitness-cost was assigned to SP-resistant gametocytes when mixed infections were taken up during a blood meal. A more detailed discussion of these assumptions and limitations is provided in [Appendix G](#appsec7){ref-type="sec"}.

The effect of antimalarial treatment on gametogenesis and infectiousness differs depending on the antimalarial class. A key assumption in using poor quality SP as a proxy for the use of all poor quality antimalarial use is that we assume that all antimalarials have the same propensity to generate gametocytes and effect on gametocyte infectiousness, which is not the case. For example, ACT use is associated with a lower rate of gametocyte carriage ([@bib7]), highlighting the need for further studies.

5. Conclusions {#sec5}
==============

The model predicts that an increase in the use of poor quality antimalarials, for which SP is an appropriate proxy, results in an increase in the transmission of antimalarial resistant malaria, providing insight into the link between poor quality antimalarial medicine use and resistance. The loss of antimalarial effectiveness is hampering malaria eradication efforts worldwide, and the continued availability and use of falsified, substandard, degraded and non-WHO recommended antimalarials are highly likely to facilitate the spread of resistance. In order to continue to effectively eradicate malaria, the availability and use of these antimalarials must be addressed by drug regulatory authorities and international organisations.
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Appendix A. Defining the deterministic model {#appsec1}
============================================

A1. Ordinary differential equations {#appsec1.1}
-----------------------------------

$$\frac{dS\left( H \right)_{w}S\left( H \right)_{r}}{dt} = \text{α}_{H} \times N_{H} - \beta_{H,w} \times S\left( H \right)_{w}S\left( H \right)_{r} \times I\left( M \right)_{w} - \beta_{H,r} \times S\left( H \right)_{w}S\left( H \right)_{r} \times I\left( M \right)_{r} + I\left( H \right)_{w}S\left( H \right)_{r}\left\lbrack {\theta_{q} \times \gamma_{w,q} + \theta_{m} \times \gamma_{w,m} + \theta_{p} \times \gamma_{w,p} + \theta_{n} \times \gamma_{n}} \right\rbrack + \theta_{q} \times \gamma_{wr,q} \times I\left( H \right)_{w}I\left( H \right)_{r} + S\left( H \right)_{w}I\left( H \right)_{r}\left\lbrack {\theta_{q} \times \gamma_{r,q} + \theta_{m} \times \gamma_{r,m} + \theta_{p} \times \gamma_{r,p} + \theta_{n} \times \gamma_{n}} \right\rbrack + \rho \times R\left( H \right) - \mu_{O} \times S\left( H \right)_{w}S\left( H \right)_{r}$$$$\frac{dE\left( H \right)_{w}S\left( H \right)_{r}}{dt} = \beta_{H,w} \times S\left( H \right)_{w}S\left( H \right)_{r} \times I\left( M \right)_{w} - \beta_{H,r} \times E\left( H \right)_{w}S\left( H \right)_{r} \times I\left( M \right)_{r} - \sigma_{H} \times E\left( H \right)_{w}S\left( H \right)_{r} + E\left( H \right)_{w}I\left( H \right)_{r}\left\lbrack {\theta_{q} \times \gamma_{r,q} + \theta_{m} \times \gamma_{r,m} + \theta_{p} \times \gamma_{r,p} + \theta_{n} \times \gamma_{n}} \right\rbrack - \mu_{O} \times E\left( H \right)_{W}S\left( H \right)_{r}$$$$\frac{dI\left( H \right)_{w}S\left( H \right)_{r}}{dt} = \sigma_{H} \times E\left( H \right)_{w}S\left( H \right)_{r} - \beta_{H,r} \times I\left( H \right)_{w}S\left( H \right)_{r} \times I\left( M \right)_{r} - I\left( H \right)_{w}S\left( H \right)_{r}\left\lbrack \theta_{q} \times \gamma_{w,q} + \theta_{m} \times \gamma_{w,m} + \theta_{p} \times \gamma_{w,p} + \theta_{n} \times \gamma_{n} \right\rbrack + \frac{1}{2} \times \theta_{n} \times \gamma_{n} \times I\left( H \right)_{w}I\left( H \right)_{r} - \gamma_{R} \times I\left( H \right)_{w}S\left( H \right)_{r} - \mu_{I} \times I\left( H \right)_{w}S\left( H \right)_{r}$$$$\frac{dS\left( H \right)_{w}E\left( H \right)_{r}}{dt} = \beta_{H,r} \times S\left( H \right)_{w}S\left( H \right)_{r} \times I\left( M \right)_{r} - \beta_{H,w} \times S\left( H \right)_{w}E\left( H \right)_{r} \times I\left( M \right)_{w} - \sigma_{H} \times S\left( H \right)_{w}E\left( H \right)_{r} + I\left( H \right)_{w}E\left( H \right)_{r}\left\lbrack {\theta_{q} \times \gamma_{w,q} + \theta_{m} \times \gamma_{w,m} + \theta_{p} \times \gamma_{w,p} + \theta_{n} \times \gamma_{n}} \right\rbrack - \mu_{O} \times S\left( H \right)_{w}E\left( H \right)_{r}$$$$\frac{dE\left( H \right)_{w}E\left( H \right)_{r}}{dt} = \beta_{H,w} \times S\left( H \right)_{w}E\left( H \right)_{r} \times I\left( M \right)_{w} + \beta_{H,r} \times E\left( H \right)_{w}S\left( H \right)_{r} \times I\left( M \right)_{r} - 2 \times \sigma_{H} \times E\left( H \right)_{w}E\left( H \right)_{r} - \mu_{O} \times E\left( H \right)_{w}E\left( H \right)_{r}$$$$\frac{dI\left( H \right)_{w}E\left( H \right)_{r}}{dt} = \beta_{H,r} \times I\left( H \right)_{w}S\left( H \right)_{r} \times I\left( M \right)_{r} + \sigma_{H} \times E\left( H \right)_{w}E\left( H \right)_{r} - \sigma_{H} \times I\left( H \right)_{w}E\left( H \right)_{r} - I\left( H \right)_{w}E\left( H \right)_{r}\left\lbrack {\theta_{q} \times \gamma_{w,q} + \theta_{m} \times \gamma_{w,m} + \theta_{p} \times \gamma_{w,p} + \theta_{n} \times \gamma_{n}} \right\rbrack - \gamma_{R} \times I\left( H \right)_{w}E\left( H \right)_{r} - \mu_{I} \times I\left( H \right)_{w}E\left( H \right)_{r}$$$$\frac{dS\left( H \right)_{w}I\left( H \right)_{r}}{dt} = \sigma_{H} \times S\left( H \right)_{w}E\left( H \right)_{r} - \beta_{H,w} \times S\left( H \right)_{w}I\left( H \right)_{r} \times I\left( M \right)_{w} - S\left( H \right)_{w}I\left( H \right)_{r}\left\lbrack {\theta_{q} \times \gamma_{r,q} + \theta_{m} \times \gamma_{r,m} + \theta_{p} \times \gamma_{r,p} + \theta_{n} \times \gamma_{n}} \right\rbrack + I\left( H \right)_{w}I\left( H \right)_{r}\left\lbrack {\theta_{q} \times \gamma_{wr,q} + \theta_{m} \times \gamma_{wr,m} + \theta_{p} \times \gamma_{wr,p} + \frac{1}{2} \times \theta_{n} \times \gamma_{n}} \right\rbrack - \gamma_{R} \times S\left( H \right)_{w}I\left( H \right)_{r} - \mu_{I} \times S\left( H \right)_{w}I\left( H \right)_{r}$$$$\frac{dE\left( H \right)_{w}I\left( H \right)_{r}}{dt} = \beta_{H,w} \times S\left( H \right)_{w}I\left( H \right)_{r} \times I\left( M \right)_{w} + \sigma_{H} \times E\left( H \right)_{w}E\left( H \right)_{r} - \sigma_{H} \times E\left( H \right)_{w}I\left( H \right)_{r} - E\left( H \right)_{w}I\left( H \right)_{r}\left\lbrack {\theta_{q} \times \gamma_{r,q} + \theta_{m} \times \gamma_{r,m} + \theta_{p} \times \gamma_{r,p} + \theta_{n} \times \gamma_{n}} \right\rbrack - \gamma_{R} \times E\left( H \right)_{w}I\left( H \right)_{r} - \mu_{I} \times E\left( H \right)_{w}I\left( H \right)_{r}$$$$\frac{dI\left( H \right)_{w}I\left( H \right)_{r}}{dt} = \sigma_{H} \times E\left( H \right)_{w}I\left( H \right)_{r} + \sigma_{H} \times I\left( H \right)_{w}E\left( H \right)_{r} - I\left( H \right)_{w}I\left( H \right)_{r}\left\lbrack {\theta_{q} \times \gamma_{wr,q} + \theta_{m} \times \gamma_{wr,m} + \theta_{p} \times \gamma_{wr,p} + \theta_{n} \times \gamma_{n}} \right\rbrack - \gamma_{R} \times I\left( H \right)_{w}I\left( H \right)_{r} - \mu_{I} \times I\left( H \right)_{w}I\left( H \right)_{r}$$$$\frac{dR\left( H \right)}{dt} = \gamma_{R} \times \left\lbrack {I\left\lbrack H \right\rbrack_{w}S\left\lbrack H \right\rbrack_{r} + I\left\lbrack H \right\rbrack_{w}E\left\lbrack H \right\rbrack_{r} + I\left\lbrack H \right\rbrack_{w}I\left\lbrack H \right\rbrack_{r} + S\left\lbrack H \right\rbrack_{w}I\left\lbrack H \right\rbrack_{r} + E\left\lbrack H \right\rbrack_{w}I\left\lbrack H \right\rbrack_{r}} \right\rbrack - \rho \times R\left( H \right) - \mu_{O} \times R\left( H \right)$$$$\frac{dD\left( H \right)_{I}}{dt} = \mu_{I}\left\lbrack {I\left( H \right)_{w}S\left( H \right)_{r} + I\left( H \right)_{w}E\left( H \right)_{r} + S\left( H \right)_{w}I\left( H \right)_{r} + E\left( H \right)_{w}I\left( H \right)_{r} + I\left( H \right)_{w}I\left( H \right)_{r}} \right\rbrack$$$$\frac{dD\left( H \right)_{O}}{dt} = \mu_{O}\left\lbrack {S\left\lbrack H \right\rbrack_{w}S\left\lbrack H \right\rbrack_{r} + E\left\lbrack H \right\rbrack_{w}S\left\lbrack H \right\rbrack_{r} + S\left\lbrack H \right\rbrack_{w}E\left\lbrack H \right\rbrack_{r} + E\left\lbrack H \right\rbrack_{w}E\left\lbrack H \right\rbrack_{r} + R\left\lbrack H \right\rbrack} \right\rbrack$$$$\frac{dS\left( M \right)}{dt} = \text{Ω}_{M} \times N_{M} - \beta_{M,w} \times S\left( M \right)\left\lbrack {I\left\lbrack H \right\rbrack_{w}S\left\lbrack H \right\rbrack_{r} + I\left\lbrack H \right\rbrack_{w}E\left\lbrack H \right\rbrack_{r} + P_{w} \times I\left\lbrack H \right\rbrack_{w}I\left\lbrack H \right\rbrack_{r}} \right\rbrack - \beta_{M,r} \times S\left( M \right)\left\lbrack {S\left\lbrack H \right\rbrack_{w}I\left\lbrack H \right\rbrack_{r} + E\left\lbrack H \right\rbrack_{w}I\left\lbrack H \right\rbrack_{r} + \left\lbrack {1 - P_{w}} \right\rbrack \times I\left\lbrack H \right\rbrack_{w}I\left\lbrack H \right\rbrack_{r}} \right\rbrack - \mu_{M} \times S\left( M \right)$$$$\frac{dE\left( M \right)_{w}}{dt} = \beta_{M,w} \times S\left( M \right)\left\lbrack {I\left( H \right)_{w}S\left( H \right)_{r} + I\left( H \right)_{w}E\left( H \right)_{r} + P_{w} \times I\left( H \right)_{w}I\left( H \right)_{r}} \right\rbrack - \sigma_{M} \times E\left( M \right)_{w} - \mu_{M} \times E\left( M \right)_{w}$$$$\frac{dI\left( M \right)_{w}}{dt} = \ \sigma_{M} \times E\left( M \right)_{w} - \mu_{M} \times I\left( M \right)_{w}$$$$\frac{dE\left( M \right)_{r}}{dt} = \beta_{M,r} \times S\left( M \right)\left\lbrack {S\left\lbrack H \right\rbrack_{w}I\left\lbrack H \right\rbrack_{r} + E\left\lbrack H \right\rbrack_{w}I\left\lbrack H \right\rbrack_{r} + \left\lbrack {1 - P_{w}} \right\rbrack \times I\left\lbrack H \right\rbrack_{w}I\left\lbrack H \right\rbrack_{r}} \right\rbrack - \sigma_{M} \times E\left( M \right)_{r} - \mu_{M} \times E\left( M \right)_{r}$$$$\frac{dI\left( M \right)_{r}}{dt} = \sigma_{M} \times E\left( M \right)_{r} - \mu_{M} \times I\left( M \right)_{r}$$$$\frac{dD\left( M \right)}{dt} = \mu_{M}\left\lbrack {\text{S}\left( \text{M} \right) + E\left( M \right)_{w} + E\left( M \right)_{r} + I\left( M \right)_{w} + I\left( M \right)_{r}} \right\rbrack$$

A2. Initial conditions {#appsec1.2}
----------------------

The set of initial conditions for each class of the model are defined in [Table A2.1](#dtbla1){ref-type="table"}.Table A2.1Initial Conditions. The initial values of each class in the model (i.e. when time is set to 0).Table A2.1PopulationModel ClassInitial Value $\left( {t = 0} \right)$Human$N_{H}$$1.0000$$E\left( H \right)_{w}S\left( H \right)_{r}$$0.0021$$I\left( H \right)_{w}S\left( H \right)_{r}$$0.0009$$S\left( H \right)_{w}E\left( H \right)_{r}$$0.0108$$E\left( H \right)_{w}E\left( H \right)_{r}$$0.0000$$I\left( H \right)_{w}E\left( H \right)_{r}$$0.0000$$S\left( H \right)_{w}I\left( H \right)_{r}$$0.0046$$E\left( H \right)_{w}I\left( H \right)_{r}$$0.0000$$I\left( H \right)_{w}I\left( H \right)_{r}$$0.0000$$R\left( H \right)$$0.0000$$D\left( H \right)_{I}$$0.0000$$D\left( H \right)_{O}$$0.0000$$S\left( H \right)_{w}S\left( H \right)_{r}$$N_{H} - \left\lbrack E\left( H \right)_{w}S\left( H \right)_{r} + I\left( H \right)_{w}S\left( H \right)_{r} + S\left( H \right)_{w}E\left( H \right)_{r} + E\left( H \right)_{w}E\left( H \right)_{r} + I\left( H \right)_{w}E\left( H \right)_{r} + S\left( H \right)_{w}I\left( H \right)_{r} + E\left( H \right)_{w}I\left( H \right)_{r} + I\left( H \right)_{w}I\left( H \right)_{r} + R\left( H \right) + D\left( H \right)_{I} + D\left( H \right)_{O} \right\rbrack$Mosquito$N_{M}$$0.8700$$E\left( M \right)_{w}$$0.0002$$E\left( M \right)_{r}$$0.0012$$I\left( M \right)_{w}$$0.0017$$I\left( M \right)_{r}$$0.0088$$D\left( M \right)$$0.0000$$S\left( M \right)$$N_{M} - \left\lbrack {E\left( M \right)_{w} + E\left( M \right)_{r} + I\left( M \right)_{w} + I\left( M \right)_{r} - D\left( M \right)} \right\rbrack$

B. Human parameters {#appsec2}
===================

The model parameters for the human population are defined in [Table B.1](#dtbla2){ref-type="table"}, along with the parameter values used, the parameter range, and the published reference or the section of the Appendices where this parameter is defined.Table B.1**Human Parameters**. A description of the parameters specific to the human population, in Kenya (2006). For parameter values where literature values were readily available, these values, along with the range of values and references are provided. For parameters that required further manipulation from the original source, the section of the Appendices where this parameter is discussed is noted. All parameter units are in days, unless otherwise stated.Table B.1Parameter descriptionSymbolValue \[range\]ReferenceHuman Kenyan population (count)$Y_{K}$36,757,498[@bib60]Number of deaths in Kenya in 2006 (count)$D_{K}$11 per 1000[@bib56]Births per year in Kenya$\chi$38 per 1000[@bib54]Range of child-bearing ages (years of age): initial, final$\lambda_{I}$, $\lambda_{F}$15, 49[@bib23]Fertility rate (births per woman)$\zeta$$4.9$[@bib57]Proportion of population that are female$\psi$0.501[@bib59]Life expectancy of humans (days)$\xi_{H}$20,454[@bib58]Kenyan 2006 malaria cases (count)$Y_{M}$8,926,058[@bib64]Kenyan 2006 malarial deaths (count)$D_{M}$74,970[@bib56], [@bib64]Latency period of asexual parasites in humans (days)$\text{Π}_{\text{Η}}$9 \[9, 14\][@bib6]Delay in seeking treatment (days)$\eta$1 \[0, 2\][@bib49]Time to initial wave of gametocytes after the initial wave of asexual parasites (days)$G_{I}$7 \[7, 15\][@bib7]Time for gametocytes to mature (days)$G_{M}$2 \[2, 3\][@bib7]Total time until infectious gametocytes (days) from time of transmission from mosquito$\upsilon$18 \[18, 32\][Appendix B3](#appsec2.3){ref-type="sec"}Rate of the loss of acquired immunity$\rho$0.0027[@bib28]Allele frequency of SP-sensitive *P. falciparum*$F_{w}$0.50 \[0.05, 0.50\][@bib27]Allele frequency of SP-resistant *P. falciparum*$F_{r}$0.42 \[0.42, 0.90\][@bib27], [@bib47]Allele frequency of mixed *P. falciparum*$F_{wr}$0.08 \[0, 0.08\][@bib27]The rate of building effective immunity$q$27.3774[@bib28]The rate of recovery of *P. falciparum* infection$s$0.0018[@bib28]

B1. Human birth rate $\left( \text{Ω}_{\text{Η}} \right)$ {#appsec2.1}
---------------------------------------------------------

Equations [(B1.1)](#fdB1_1){ref-type="disp-formula"}, [(B1.2)](#fdB1_2){ref-type="disp-formula"} were used to calculate a parameter range for the daily birth rate of humans $\left( \text{Ω}_{\text{Η}} \right)$, resulting parameter range for daily birth rate of humans $\left( \text{Ω}_{\text{Η}} \right)$ was$1.0411 \times 10^{- 4}$ -$7.811 \times 10^{- 4}$.$$\text{Ω}_{\text{Η}} = \frac{\chi}{365}$$$$\zeta = \text{Ω}_{\text{Η}} \times \psi \times \frac{\left( \lambda_{F} - \lambda_{I} \right)}{\frac{\xi_{H}}{365}} \times \xi_{H}$$where $\chi$ denotes the number of births in Kenya, in 2006; $\zeta$ denotes the average number of births per female; $\text{Ω}_{\text{Η}}$ denotes the daily birth rate of humans; $\psi$ denotes the proportion of Kenyan population that are female; $\frac{\left( \lambda_{F} - \lambda_{I} \right)}{\frac{\xi_{H}}{365}}$ denotes the probability of being of childbearing age; and $\xi_{H}$ denotes the expected human lifespan (days).

B2. Movement from susceptible to exposed classes $\left( \beta_{H,i} \right)$ {#appsec2.2}
-----------------------------------------------------------------------------

The expected rate of movement of humans from being susceptible to exposed to *P. falciparum,* during a blood meal when sporozoites are introduced through the salivary gland of the female *An.* mosquito, is defined by$$\beta_{H,i} = c \times T_{i}$$where $i$ denotes the *P. falciparum* strain ($i = w$ for SP-sensitive or $i = r$ for SP-resistant); $c$ denotes the female *An.* mosquito daily biting rate; and $T_{i}$ denotes the transmission probability of strain $i$ from mosquito to human.

B3. Movement from exposed to infected $\left( \sigma_{H} \right)$ {#appsec2.3}
-----------------------------------------------------------------

The expected time to infectious gametocytes, $\upsilon$, in days is defined by$$\upsilon = \text{Π}_{\text{Η}} + G_{I} + G_{M}$$where $\text{Π}_{\text{Η}}$ denotes the latency period of asexual parasites in humans (days); $G_{I}$ denotes the time until the initial wave of asexual *P. falciparum* (days); and $G_{M}$ denotes the time for gametocytes to mature in order to be infectious to female *An.* mosquitoes (days).

Therefore, the rate of human movement from being exposed to *P. falciparum* (during a blood meal), to being infectious (mature gametocytes), is given by$$\text{σ}_{\text{H}} = \frac{1}{\upsilon}$$where $\upsilon$ denotes the expected time to infectious gametocytes (days).

B4. Movement from infected to susceptible $\left( \gamma_{i.d} \right)$ {#appsec2.4}
-----------------------------------------------------------------------

The estimated daily rate of recovery $\gamma_{i,d}$ is defined by$$\gamma_{i,d} = \frac{1}{\text{Π}_{\text{Η}} + \eta + \ \varepsilon_{i,d} - \upsilon}$$where $i = w$ for SP-sensitive *P. falciparum*, $i = r$ for SP-resistant *P. falciparum*, $i = wr$ for mixed *P. falciparum* infection; $d = q$ for good quality AL treatment, $d = m$ for full-dose SP treatment, $d = p$ for half-dose SP treatment and $d = n$ for no antimalarial treatment; $\text{Π}_{\text{Η}}$ denotes the latency period of asexual *P. falciparum* in humans (days); $\eta$ denotes the delay in seeking treatment (days); $\varepsilon_{i,d}$ denotes the estimated time to recovery in days (see [Appendix C2](#appsec3.2){ref-type="sec"}); and $\upsilon$ denotes the expected time to infectious gametocytes (days) (Eq. [(B3.1)](#fdB3_1){ref-type="disp-formula"}).

B5. Movement from infected to acquired immunity $\left( \gamma_{R} \right)$ {#appsec2.5}
---------------------------------------------------------------------------

Immunity to malaria is defined by [@bib10] as "the state of resistance to infection brought about by all those processes which are involved in destroying the plasmodia or by limiting their multiplication", and can be passive or active. Passive immunity is conferred from mother to child or through vaccinations ([@bib16]). For the purposes of this model, we assume passive immunity cannot be gained. Actively acquired immunity is assumed to be temporarily gained after continuous exposure, as used in the model by [@bib28]. Acquired immunity has been found to be delayed in the presence of intermittent or prophylaxis treatment ([@bib16]), and additionally in full dose treatment, as parasites are eradicated ([@bib30]). In research carried out by [@bib30] on mice, lower doses of antimalarial treatment better enabled the mice to acquire protective immunity than the higher doses. We assume that once acquired immunity is gained, protection is afforded against both SP-sensitive and SP-resistant infections.

The maximum expected rate of acquired immunity gained is defined by Eq. [(B5.1)](#fdB5_1){ref-type="disp-formula"} ([@bib28]), resulting in the parameter range for $\gamma_{R}$ of \[0, 0.0018\].$$\gamma_{R} = \frac{q \times s}{q + s}$$where $\gamma_{R}$ denotes the rate acquired immunity is gained; $q$ denotes the daily rate of building effective immunity; and $s$ denotes the daily rate of recovery.

B6. Human mortality rates ($\mu_{O}$ and $\mu_{I}$) {#appsec2.6}
---------------------------------------------------

The two different reported values for total human mortality in Kenya in 2006 are:•The World Bank states 11 deaths per 1000 population, equating to a count of 404,332 deaths ([@bib56]).•The WHO World Malaria Report states that there were 216,158 deaths in total, with 40,079 as a result of malaria ([@bib64]).

The difference in estimates of mortality provided by the World Bank and the WHO World Malaria Report indicates the possibility of under-reporting in the estimates obtained by the WHO, for both overall and malaria-specific mortality. The number of malaria deaths reported by the WHO was adjusted by an "under-reporting" factor calculated in Eq. [(B6.1)](#fdB6_1){ref-type="disp-formula"}.$$Estimated\ Malaria\ Deaths\left( {count} \right) = \frac{40079}{216158} \times 404332 = 74970$$

The daily rate of mortality is defined into two groups: (i) *malaria-specific* mortality $\left( \mu_{I} \right)$ and (ii) *other* mortality $\left( \mu_{O} \right)$. *Malaria-specific* mortality occurs once humans are within the infected class; and *other* deaths occur in all other classes of the model, where these non-malarial associated deaths may be due to other illnesses, old age, accidents, among other causes.

The calculation for the daily rate of *malaria-specific* mortality $\left( \mu_{I} \right)$ is defined below. The proportion of those infected with *P. falciparum* who die, $x$, in 2006 is$$x = \frac{Malaria\ Deaths}{Malaria\ Cases} = 0.0084$$

An estimate of the overall rate of recovery from infected to susceptible classes, $\overline{\gamma}$, at baseline is:$$\overline{\gamma} = \sum\limits_{i}F_{i}\sum\limits_{d}\theta_{d}\gamma_{i,d} = F_{w}\left( {\theta_{q}\gamma_{w,q} + \theta_{m}\gamma_{w,m} + \theta_{p}\gamma_{w,p} + \theta_{n}\gamma_{n}} \right) + F_{r}\left( {\theta_{q}\gamma_{r,q} + \theta_{m}\gamma_{r,m} + \theta_{p}\gamma_{r,p} + \theta_{n}\gamma_{n}} \right) + F_{wr}\left( {\theta_{q}\gamma_{wr,q} + \theta_{m}\gamma_{wr,m} + \theta_{p}\gamma_{wr,p} + \theta_{n}\gamma_{n}} \right) = 0.6821$$

Therefore, the daily rate of *malaria-specific* mortality $\left( \mu_{I} \right)$ while the human is infected (i.e. has infectious gametocytes) is approximately:$$\mu_{I} = x \times \frac{\mu_{H} + \theta_{n}\gamma_{R} + \overline{\gamma}}{1 - x} = \ 0.0058$$

It must be noted that the estimate of malaria-specific mortality does not include the time period the patient is in the exposed class and symptomatic (asexual *P. falciparum*) but not infectious (mature gametocytes). In addition to this, the calculation for mortality is affected by the percentage use of antimalarial medicines. For this reason, it was defined at the 2006 baseline and cannot be explored under different drug use scenarios (results section). Finally, this calculation assumes that the "total population *minus* malaria cases" is an accurate estimate of the number of people who do not get malaria. It must be noted that people can get more than one malaria infection within the calendar year.

The *other* mortality $\left( \mu_{O} \right)$ is assumed to be approximately equal to the overall mortality rate in humans $\left( \mu_{H} \right)$, defined as 1/(life expectancy), because the proportion of those with malaria who die is so small (see Eq. [(B6.4)](#fdB6_4){ref-type="disp-formula"}).$$\mu_{H} = \frac{1}{\text{ξ}_{H}} = \frac{1}{56 \times 365} = 4.8924 \times 10^{- 5} \cong \mu_{O}$$

C. Treatment parameters {#appsec3}
=======================

The treatment-based model parameters are defined in [Table C.1](#dtbla3){ref-type="table"}, along with the parameter values used, the parameter range, and the published reference or the section of the Appendices where this parameter is defined.Table C.1**Treatment parameters**. A description of the treatment parameters used in the model. For parameter values where literature values were readily available, these values, along with the range of values and references are provided. For parameters that required further manipulation from the original source, the section of the Appendices where this parameter is discussed is noted. All parameter units are in days, unless otherwise stated.Table C.1SymbolParameter descriptionValue \[range or $\pm 10\%$\]Reference$1 - \theta_{n}$Probability of receiving treatment0.80 \[0.80, 0.91\][@bib13]$\theta_{n}$Receiving no treatment (proportion, at baseline)0.20 \[0.09, 0.20\][@bib13]$\theta_{m}$Receiving full-dose SP monotherapy (proportion, at baseline)0.07 \[0.063, 0.077\][@bib15]$\theta_{p}$Receiving half-dose SP monotherapy (proportion, at baseline)0.03 \[0.027, 0.33\][Appendix C1](#appsec3.1){ref-type="sec"}$\theta_{q}$Receiving AL (proportion, at baseline)0.70 \[0.63, 0.77\][Appendix C1](#appsec3.1){ref-type="sec"}$\varepsilon_{w,q}$SP-sensitive gametocyte clearance in humans treated with AL14 \[12.6, 15.4\][Appendix C2.1](#appsec3.2.1){ref-type="sec"}$\varepsilon_{r,q}$SP-resistant gametocyte clearance in humans treated with AL14 \[12.6, 15.4\][Appendix C2.1](#appsec3.2.1){ref-type="sec"}$\varepsilon_{wr,q}$Mixed infection gametocyte clearance in humans treated with AL14 \[12.6, 15.4\][Appendix C2.1](#appsec3.2.1){ref-type="sec"}$\varepsilon_{w,m}$SP-sensitive gametocyte clearance in humans treated with full-dose SP monotherapy25 \[21, 119\][Appendix C2.2](#appsec3.2.2){ref-type="sec"}$\varepsilon_{r,m}$SP-resistant gametocyte clearance in humans treated with full-dose SP monotherapy112 \[112, 882\][Appendix C2.2](#appsec3.2.2){ref-type="sec"}$\varepsilon_{wr,m}$Mixed infection gametocyte clearance in humans treated with full-dose SP monotherapy25 \[21, 119\][Appendix C2.2](#appsec3.2.2){ref-type="sec"}$\varepsilon_{w,p}$SP-sensitive gametocyte clearance in humans treated with half-dose SP monotherapy29 \[29, 162\][Appendix C2.2](#appsec3.2.2){ref-type="sec"}$\varepsilon_{r,p}$SP-resistant gametocyte clearance in humans treated with half -dose SP monotherapy112 \[112, 882\][Appendix C2.2](#appsec3.2.2){ref-type="sec"}$\varepsilon_{wr,p}$Mixed infection gametocyte clearance in humans treated with half -dose SP monotherapy92 \[92, 772\][Appendix C2.2](#appsec3.2.2){ref-type="sec"}$\varepsilon_{n}$Gametocyte clearance in humans not treated75 \[0, 730\][@bib2]$Z_{w,q}$SP-sensitive gametocyte transmission when treated with AL (probability)0.053705 \[0.0183335, 0.053705\][Appendix C3.3](#appsec3.3.3){ref-type="sec"}$Z_{r,q}$SP-resistant gametocyte transmission when treated with AL (probability)0.053705 \[0.0183335, 0.053705\][Appendix C3.3](#appsec3.3.3){ref-type="sec"}$Z_{wr,q}$Mixed infection gametocyte transmission when treated with AL (probability)0.053705 \[0.0183335, 0.053705\][Appendix C3.3](#appsec3.3.3){ref-type="sec"}$Z_{w,m}$SP-sensitive gametocyte transmission when treated with full-dose SP (probability)0.055 \[0.0495, 0.0605\][Appendix C3.2](#appsec3.3.2){ref-type="sec"}$Z_{r,m}$SP-resistant gametocyte transmission when treated with full-dose SP (probability)0.3 \[0.424485, 0.4999\][Appendix C3.2](#appsec3.3.2){ref-type="sec"}$Z_{wr,m}$Mixed infection gametocyte transmission when treated with full-dose SP (probability)0.31 \[0.452, 0.527375\][Appendix C3.2](#appsec3.3.2){ref-type="sec"}$Z_{w,p}$SP-sensitive gametocyte transmission when treated with half-dose SP (probability)0.0489 \[0.04401, 0.05379\][Appendix C3.2](#appsec3.3.2){ref-type="sec"}$Z_{r,p}$SP-resistant gametocyte transmission when treated with half-dose SP (probability)0.0147 \[0.0125, 0.0147\][Appendix C3.2](#appsec3.3.2){ref-type="sec"}$Z_{wr,p}$Mixed infection gametocyte transmission when treated with half-dose SP (probability)0.1913 \[0.1639, 0.1913\][Appendix C3.2](#appsec3.3.2){ref-type="sec"}$Z_{n}$Gametocyte transmission with no treatment (probability)0.2 \[0.2, 0.5\][@bib32], [Appendix C3.1](#appsec3.3.1){ref-type="sec"}

C1. Percentage drug use $\left( \theta_{d} \right)$ {#appsec3.1}
---------------------------------------------------

[@bib13] investigated treatment seeking behaviour of those residing in Kenya. During the two week period of the study, the percentage of people with acute illnesses that did not use treatment was 9.3% in urban areas and 20.1% in rural areas. Therefore, we parameterised the proportion of those who do not seek treatment $\left( \theta_{n} \right)$ as ranging from 0.09 to 0.20. This leads to the understanding that those who seek treatment $\left( {1 - \theta_{n}} \right)$ ranges from 0.80 to 0.91.

The 2003 Demographic Health Survey (DHS) was used to estimate the percentage of SP used within the community. The survey reported the treatment practises of parents with children under five years old, and it was identified that 10.9% received SP ([@bib15]).

Insight into the quality of antimalarial medicines, especially the percentage of falsified medicines, has been informed by numerous studies; however, accurate estimates are hard to come by. In 2006, [@bib38] estimated the percentage of falsified medicines ranges from 1% to 50% worldwide. An analysis of the WorldWide Antimalarial Resistance Network database found that out of 9348 antimalarial medicines sampled, 30.1% failed chemical or packaging quality tests, of which: 39.3% were classified as falsified; 2.3% as substandard medicines; and 58.3% poor quality without evidence available to classify them as substandard or falsified ([@bib51]). A study released in 2003, analysing the quality of SP tablets sold by private wholesale pharmacies in Dar Es Salaam, Tanzania, found that 8/18 (44%) of SP samples failed assay tests for content and dissolution tests ([@bib37]).

Following this evidence, the probability of receiving full-dose SP $\left( \theta_{m} \right)$ was set to 0.07; the probability of receiving half-dose SP $\left( \theta_{p} \right)$ was set to 0.03; the probability of not receiving any antimalarial treatment $\left( \theta_{n} \right)$ was set to 0.20; and the probability of receiving AL treatment $\left( \theta_{q} \right)$ was assumed to be the remainder (Eq. [(C1.1)](#fdC1_1){ref-type="disp-formula"}), at baseline.$$\theta_{q} = 1 - \left( {\theta_{m} + \theta_{p} + \theta_{n}} \right) = 0.70$$

C2. Gametocyte clearance (days) post-treatment $\left( \mathbf{\varepsilon}_{\mathbf{i},\mathbf{d}} \right)$ {#appsec3.2}
------------------------------------------------------------------------------------------------------------

### C2.1. Artemether-Lumefantrine treatment sought {#appsec3.2.1}

In the literature, [@bib8] found 16.0% (12 out of 75) of children treated with AL had gametocytemia on day; and [@bib50] found 7.94% (30 out of 378) treated children were carriers of gametocytes on day 28 post-treatment. However, [@bib45] found an average of $5.5$ days of gametocyte carriage post-treatment (95% CI: 3.6--8.5 days) of children treated with AL who remained asexual parasite free during follow-up.

For this reason, we feel it is a reasonable assumption that the patient has gametocytemia until day 14 and then moves back to the susceptible class, given that the number of humans carrying gametocytes past day 28 is small.$$\varepsilon_{w,q} = \varepsilon_{r,q} = \varepsilon_{wr,q} = 14\ \text{days}\left\lbrack 7,28 \right\rbrack$$where $\varepsilon_{i,\text{d}}$ denotes the estimated days for gametocyte clearance post-treatment, for *P. falciparum* strain $i$ and drug treatment $d$; and the parameter range is denoted \[minimum, maximum\].

### C2.2. Sulfadoxine-Pyrimethamine treatment sought {#appsec3.2.2}

The data used to inform the asexual and gametocyte clearance rates when treated with SP were calculated using the combination of mice data (pyrimethamine treatment) ([@bib20], [@bib22], [@bib19]) and human SP studies carried out in South Africa ([@bib4], [@bib5]) and Columbia ([@bib34]). The mice studies researched the effect of pyrimethamine (not in combination with sulfadoxine) on gametocyte densities and the length of infectivity over a maximum of 28 days ([@bib19], [@bib22]). The experimental design was developed to simulate the emergence of resistance, using two genetically distinct *P. chabaudi* clonal lineages in each study: drug-resistant AS12265 (pyr-1A) and drug-sensitive AJ5154 ([@bib19]); and drug-susceptible clone AJ5p and pyrimethamine-resistant clone AS6p(pyr1A) ([@bib22]). The experiment was carried out in six to eight week-old female C57Bl/6J laboratory mice, with treatment taking place six days post-inoculation. In mixed infections, 10^6^ pyrimethamine-sensitive parasites were inoculated, followed by ∼25 pyrimethamine-resistant parasites five days after the experiment began, to simulate the emergence of resistance. The estimates for half-dose SP treatments were calculated from experimental data using on 50% of a full dose of pyrimethamine ([@bib22]) and 37.5% of a full dose of pyrimethamine ([@bib19]). [Figure C2.2.1](#dfig1){ref-type="graphic"} shows a summary of data obtained.Fig. C2.2.1The daily *P. chabaudi* gametocyte density in mice post-pyrimethamine treatment for (A) pyrimethamine-sensitive gametocytes, (B) pyrimethamine-resistant gametocytes, and (C) mixed infection gametocytes. The purple line denotes the gametocyte density for a 100% pyrimethamine treatment. The green line denotes the gametocyte density of 37.5% of a full dose of pyrimethamine treatment for (A) and 50% of a full dose of pyrimethamine treatment for (B) and (C). Data provided by [@bib22], [@bib19], [@bib20].Fig. C2.2.1

Estimates for the expected gametocyte clearance time for humans in days, corresponding to each *P. falciparum* infection type $i$ when using half-dose SP monotherapy did not exist at the time of developing this model, so multiple studies and assumptions were used to calculate these values. Estimates of the time to recover were calculated using Eq. [(C2.2.1)](#fdC2_2_1){ref-type="disp-formula"}, where the ratio of expected recovery time of mice treated with half-dose pyrimethamine to full-dose pyrimethamine treatment is multiplied by the expected time to recovery in humans treated with full-dose SP. A summary of the parameter values obtained from the human and mice studies are provided in [Table C2.2.1](#dtbla13){ref-type="table"}.$$\varepsilon_{i,d} = E\left( H \right)_{i,m} \times \frac{E\left( M \right)_{i,p}}{E\left( M \right)_{i,m}}$$where $E\left( H \right)_{i,m}$ denotes the gametocyte clearance time in humans for each *P. falciparum* strain $i$ when treated with full-dose SP, as found by [@bib4], [@bib5]; $E\left( M \right)_{i,p\ or\ n}$ denotes the gametocyte clearance time in mice for each *P. chabaudi* strain $i$ when treated with half-dose SP $\left( p \right)$ or no treatment $\left( n \right)$, as found by [@bib19] (for $i = w$) or [@bib22] (for $i = r$ or $wr$); and $E\left( M \right)_{i,m}$ denotes the gametocyte clearance time in mice for each *P. chabaudi* strain $i$ when treated with full-dose pyrimethmaine, as found by [@bib19] (for $i = w$) or [@bib22] (for $i = r$ or $wr$).Table C2.2.1Summary findings from gametocyte clearance studies. Gametocyte clearance time in human and mice studies, along with the parameter range (\[minimum, maximum\]), for SP-sensitive $\left( w \right)$, SP-resistant $\left( r \right)$ and mixed infections $\left( {wr} \right)$ in humans ([@bib4], [@bib5], [@bib34]); and pyrimethamine-sensitive $\left( w \right)$, pyrimethamine-resistant $\left( r \right)$ and mixed infections $\left( {wr} \right)$ in mice [@bib22], [@bib19], [@bib20].Table C2.2.1Strain $\left( i \right)$Human StudiesMice StudiesFull-dose SPFull-dose SPFull-dose PyrimethamineHalf-dose PyrimethamineDrug Sensitive $\left( w \right)$49 \[21, 119\]141115Drug resistant $\left( r \right)$315 \[112, 882\]\>282222Mixed Infection $\left( {wr} \right)$315 \[112, 882\]--2218Reference(s)[@bib4], [@bib5][@bib34][@bib22], [@bib19], [@bib20][@bib22], [@bib19], [@bib20]

The expected gametocyte recovery time in days $\left( \varepsilon_{i,d} \right)$ used to parameterise the model, along with the parameter range (\[minimum, maximum\]), is provided in [Table C2.2.2](#dtbla4){ref-type="table"}.Table C2.2.2Expected gametocyte clearance in humans (days). The expected clearance of *P. falciparum* gametocytes in humans, using a linear interpolation of SP treatment in humans ([@bib4], [@bib5]) and pyrimethamine treatment in mice studies ([@bib20], [@bib22], [@bib19]), using Eq. [(C2.2.1)](#fdC2_2_1){ref-type="disp-formula"}. ^A^Estimated using mice data where the 37.5% of a full-dose of pyrimethamine treatment used ([@bib20], [@bib19]), whereas estimates from 50% of a full-dose of pyrimethamine treatment were used for the other parameter calculations ([@bib22]).Table C2.2.2Strain $\left( i \right)$Treatment $\left( d \right)$ALFull-dose SP monotherapyHalf-dose SP monotherapyDrug Sensitive $\left( w \right)$2849 \[21, 119\]67 \[29, 162\] ^A^Drug resistant $\left( r \right)$28315 \[112, 882\]315 \[112, 882\]Mixed Infection $\left( {wr} \right)$28315 \[112, 882\]258 \[92, 722\]

C3. Infectiousness of humans to mosquitoes $\left( Z_{i,d} \right)$ {#appsec3.3}
-------------------------------------------------------------------

[@bib4], [@bib5] identified a log-sigmoidal relationship between gametocyte density and infectivity to mosquitoes, with the probability of mosquito infection dependent on the prevalence, duration and density of gametocyte carriage in the human host. They further discussed that the infectivity given a "particular antimalarial treatment can be characterised as a function of blood gametocyte density and time, summing these over the acute and all subsequent recrudescence of that infection". [@bib8] comment that the infectious mosquito reservoir determines the force of infection.

### C3.1. No treatment sought {#appsec3.3.1}

When no treatment is sought the expected probability of transmission $\left( Z_{n} \right)$ is assumed equal for each infection type,$$Z_{n} = Z_{w,n} = Z_{r,n} = Z_{wr,n} = 0.2,\text{range:0}.2 - 0.5\ \left( {\text{Mandal}\ \text{et}\ \text{al}.,2011} \right)$$

### C3.2. Sulfadoxine-Pyrimethamine treatment {#appsec3.3.2}

No specific dataset exists to inform the effect of SP treatment on infectiousness, so multiple studies were used to calculate estimates. A study carried out by [@bib34] was used to calculate the probability of gametocyte transmission when treated with full-dose SP monotherapy. The study recorded the proportion of infected mosquitoes with oocysts after treatment with SP, and the infectivity of those with and without SP-conferring mutations were calculated using membrane feeding assays. Resistance was defined as the presence of DHFR-51 and DHFR-108 SP resistance-conferring mutations. [Figure C3.2.1](#dfig2){ref-type="graphic"} shows the summary of the data produced in this study.

To calculate the expected probability of transmission from humans to mosquitoes, the area under the curve was calculated and then averaged over the number of days humans were found to be infectious (see Eq. [(C3.2.1)](#fdC3_2_1){ref-type="disp-formula"} and [Fig. C3.2.1](#dfig2){ref-type="graphic"}, results in [Table C3.2.1](#dtbla5){ref-type="table"}). The calculation assumes a uniform average transmission probability, not taking into account days that humans are more "infectious" to mosquitoes than others; and that infectiousness to mosquitoes over the 28 day experimental period is indicative of the infectiousness of gametocytes in humans to mosquitoes over the timeframe of gametocytes being present (i.e. \> 28 days).$$Z_{w\ or\ r,m} = \frac{\int_{0}^{28}f\left( t \right)_{w\ or\ r,m} \cdot dt}{\varrho}$$where $Z_{w\ or\ r,m}$ denotes the average probability of transmission from humans to mosquitoes for SP-sensitive (w) or SP-resistant (r) infections treated with SP monotherapy; $\int\limits_{0}^{28}f\left( t \right)_{w\ or\ r,m} \cdot dt$ denotes the area under the gametocyte density-time curve, over 28 days; and $\varrho$ denotes the count of the number of days gametocytes are seen.Fig. C3.2.1The proportion of infected mosquitoes when exposed to (A) SP-sensitive *P. falciparum* gametocytes, (B) SP-resistant *P. falciparum* gametocytes (108 mutants only) and (C) SP-resistant *P. falciparum* gametocytes (51 and 108 mutants), from infected humans over five years of age on the Pacific Coast of Columbia, who were treated with SP monotherapy. Estimates obtained from Fig. 1 of [@bib34]. Note: length of data collection was 28 days.Fig. C2.3.2.1Table C3.2.1Total area of average gametocyte density in [Fig. C3.2.1](#dfig2){ref-type="graphic"}, produced using estimates from [@bib34].Table C2.3.2.1StrainAverage gametocyte densitySP-sensitive $\left( w \right)$0.055 SP-resistant (*r*)108-mutatnt0.424485 SP-resistant (*r)* 51 & 108 mutant0.4999

These estimates were then used to linearly interpolate the probability of transmission for mixed infections when full-dose SP monotherapy is used, and for all infections when half-dose SP monotherapy is used. As with the calculations for gametocyte clearance ([Appendix C2](#appsec3.2){ref-type="sec"}), raw mice data provided by [@bib22] was used ([Fig. C3.2.2](#dfig3){ref-type="graphic"} and [Fig. C3.2.3](#dfig4){ref-type="graphic"}). [Figure C3.2.2](#dfig3){ref-type="graphic"} shows that the mixed infection (dotted green line) appears to behave as the sum of the gametocyte densities of the SP drug-sensitive ($w$, purple line) and SP drug-resistant ($r$, blue line).Fig. C3.2.2The average gametocyte density per day in mice infected with *P. Chabaudi* and treated with pyrimethamine. The blue line denotes the pyrimethamine-sensitive (W) gametocyte density associated with pyrimethamine treatment. In like manner, the red line denotes the pyrimethamine-resistant (R) gametocyte density, and the green dotted line denotes the mixed infection (WR) gametocyte density. Data provided by [@bib22].Fig. C2.3.2.2Fig. C3.2.3Average gametocyte density of *P. Chabaudi* infected mice with (A) pyrimethamine-sensitive gametocyte treated with full-dose pyrimethamine; (B) pyrimethamine-sensitive gametocyte treated with half-dose pyrimethamine; (C) pyrimethamine-resistant gametocyte treated with full-dose pyrimethamine; (D) pyrimethamine-resistant gametocyte treated with half-dose pyrimethamine; (E) mixed infection gametocyte treated with full-dose pyrimethamine; (F) mixed infection gametocyte treated with half-dose pyrimethamine. These graphs are produced using data from [@bib22].Fig. C2.3.2.3

As the mixed infection $\left( {wr} \right)$ predominates with the resistant $\left( r \right)$ peaks in the figure, it seems safe to assume that even with the data simulation where the mice is first infected with SP drug-sensitive $\left( w \right)$ *P. falciparum* first, then SP drug-resistant $\left( r \right)$ *P. falciparum* are added after treatment has resumed at a vastly reduced number, the transmission probabilities, $Z_{wr,m} = Z_{rw,m}$.

Assuming the probability of transmission is directly proportional to gametocyte density ([Fig. C3.2.3](#dfig4){ref-type="graphic"} and [Table C3.2.2](#dtbla6){ref-type="table"}), the infectivity to mosquitoes is calculated by multiplying the "known" infectivity for treatment with full-dose SP for strain $i$, by the ratio of gametocytes when treated with full- or half-dose pyrimethamine in the mice models ([@bib19], [@bib22]), see Eq. [(C3.2.2)](#fdC3_2_2){ref-type="disp-formula"}. It must be noted, that initially 1 × 10^6^ pyrimethamine-sensitive parasites were inoculated followed five days later with ∼25 pyrimethamine-resistant parasites. We believe this experiment skews some of the results below, however a measure of the degree of skewing in uncertain. For this reason, we must clearly indicate that these values are our best estimate.$$Z_{i,p} = Z_{i,m} \times \frac{\int_{0}^{28}f\left( t \right)_{i,p} \cdot dt\ }{\int_{0}^{28}f\left( t \right)_{i,m} \cdot dt}$$where $Z_{i,m}$ denotes the infectiousness of humans to mosquitoes calculated using values from [@bib34] (Eq. [(C3.2.1)](#fdC3_2_1){ref-type="disp-formula"}); $\ \int\limits_{0}^{28}f\left( t \right)_{i,p} \cdot dt$ denotes the area under curve of the *P. falciparum* gametocytes density of strain $i$, treated with half-dose pyrimethamine $\left( a \right)$ from mice models ([@bib22]); $\int\limits_{0}^{28}f\left( t \right)_{i,m} \cdot dt$ denotes the area under curve of the *P. falciparum* gametocytes density of strain $i$, treated with full-dose pyrimethamine $\left( m \right)$ from mice models ([Table C3.2.2](#dtbla6){ref-type="table"}) ([@bib19], [@bib22]).Table C3.2.2The calculated total area of average gametocyte density in [Fig. C3.2.3](#dfig4){ref-type="graphic"}, produced using data from [@bib22].Table C 2.3.2.2StrainTreatmentFull-dose pyrimethamineHalf-dose pyrimethaminePyrimethamine-sensitive $\left( W \right)$4241.7233769.852Pyrimethamine-resistant $\left( R \right)$6698.292197.569Mixed infection $\left( {WR} \right)$10940.0153967.421

### C3.3. Artemether-Lumefantrine treatment {#appsec3.3.3}

In the literature, [@bib8] found 3.6% (27 out of 750) of randomly selected children were infectious to mosquitoes on day seven ([Table C3.3.1](#dtbla7){ref-type="table"}), whereas the children tested over two years of age were found to be 18.7% infectious to mosquitoes. [@bib45] found that 1.9% (42 out of 2292) of those treated with AL who had gametocytes were infectious to mosquitoes on day seven post treatment ([Table C3.3.2](#dtbla8){ref-type="table"}). In addition, [@bib50] found 0% (0 out of 195) children treated with AL were infectious to mosquitoes on day 28. This data has been amalgamated to produce [Fig. C3.3.1](#dfig5){ref-type="graphic"}, which explores the infectivity of children treated with AL over time.Fig. C3.3.1Combining past studies results for gametocyte infectivity to mosquitoes following AL treatment in children, as reported by [@bib8], [@bib45], [@bib50].Fig. C2.3.3.1Table C2.3.3.1Infectiousness of gametocytes to mosquitoes after AL and SP treatment. Percentage of mosquitoes that become infected in membrane-feeding assays using blood samples from randomly selected children on day 7 post-treatment, by treatment arm. (Obtained from Table B.4 of [@bib8].)Table C2.3.3.1Treatment armInfected mosquitoes, % (proportion)RR (95% CI)SP6.9 (52/750)1AL3.6 (27/750)0.52 (0.33--0.82)Table C3.3.2Infectiousness of gametocytes to mosquitoes after AL treatment. Gametocyte infectiousness among mosquitoes, by study arm. Blood samples taken on day 7 after initiation of treatment, with mosquitoes examined on day 7 after feeding. (Obtained from Table B.3 of [@bib45].)Table C2.3.3.2VariableProportion of Participants (%)Individuals participating in membrane-feeding assays, no.77Microscopy finding on feeding day Gametocyte prevalence4.2 (3/72) Gametocyte density, gametocytes/$\mu L$, geometric mean (95% CI)39.5 (18.2--85.4)Pfs25 QT-NASBA finding on feeding day Gametocyte prevalence21.7 (5/23) Individuals infecting $\geq 1$ mosquito31.1 (24/77) Infected mosquitoes, % (proportion)1.9 (44/2293) Oocysts in infected mosquitoes, no., mean \[range\]1.3 \[1, 2\]

Calculating the average area (daily) under the line of best fit of [Fig. C3.3.1](#dfig5){ref-type="graphic"},$$Z_{w,q} = Z_{r,q} = Z_{wr,q} = 0.05705$$where $Z_{w,}$ denotes the expected probability of transmission for SP-sensitive $\left( w \right)$ gametocytes from an infected human to mosquito; and $q$ denotes the percentage use of AL treatment; $m$ denotes the percentage use of full-dose SP; and $n$ denotes the percentage who receive no treatment.

The line of best fit in [Fig. C3.3.1](#dfig5){ref-type="graphic"} indicates a poor fitting line (low R^2^); however the calculated estimates of infectiousness are consistent with a study by [@bib34], where they found that SP-resistant parasites are 7--10 times more likely to infect mosquitoes after SP treatment, compared to no resistance.

A summary of the expected probability of transmission of gametocytes of strain $\left( i \right)$ from human to mosquito during a blood meal, given the human drug treatment $\left( d \right)$ received by the human, is provided in [Table C3.3.3](#dtbla9){ref-type="table"}.Table C3.3.3A summary of the expected probability of transmission of each *P. falciparum* strain $\left( i \right)$ from human to mosquito during a blood meal, given the antimalarial treatment. ^A^Low values believed to be a product of the experimental design to collect data.Table C2.3.3.3Strain $\left( i \right)$Treatment $\left( d \right)$AL $\left( q \right)$Full-dose SP $\left( m \right)$Half-dose SP $\left( p \right)$No Treatment $\left( n \right)$SP-sensitive $\left( w \right)$0.057050.0550.04890.200SP-resistant $\left( r \right)$ 108 mutant0.057050.4244850.0125 ^A^ 58 & 108 mutant0.49990.0147 ^A^0.200Mixed infection (*wr*) 108 mutant0.057050.4520.1639 ^A^ 58 & 108 mutant0.5273750.1913 ^A^0.200

D. Transmission parameters {#appsec4}
==========================

The transmission-based model parameters are defined in [Table D.1](#dtbla10){ref-type="table"}, along with the parameter values used, the parameter range, and the published reference or the Appendix reference where this parameter is defined.Table D.1**Transmission parameters**. A description of the transmission parameters used in the model. For parameter values where literature values were readily available, these values, along with the range of values and references are provided. For parameters that required further manipulation from the original source, the section of the Appendices where this parameter is discussed is noted. All parameter units are in days, unless otherwise stated.Table D.1SymbolParameter descriptionValue \[range\]Reference$c$Biting rate of female *An.* Mosquitoes0$\cdot$ 4050 \[0.01, 0.5\][@bib2], [@bib32]$T_{w}$SP-sensitive sporozoite transmission (probability)0.2 \[0.2, 0.5\][@bib32]$T_{r}$SP-resistant sporozoite transmission (probability)0.2 \[0.2, 0.5\][@bib32]${\widetilde{Z}}_{w}$Overall transmission of SP-sensitive gametocytes (probability)0.1459 \[0.1313, 0.1605\][Appendix D2](#appsec4.2){ref-type="sec"}${\widetilde{Z}}_{r}$Overall transmission of SP-resistant gametocytes (probability)0.1410 \[0.1269, 0.1551\][Appendix D2](#appsec4.2){ref-type="sec"}$P_{w}$Fitness cost of resistance0.6 \[0.54, 0.66\][Appendix D1](#appsec4.1){ref-type="sec"}

D1. Fitness cost in mosquito midgut $\left( P_{w} \right)$ {#appsec4.1}
----------------------------------------------------------

The benefit that antimalarial resistance affords to a *Plasmodium* parasite may also cause a fitness cost ([@bib17]). A study conducted by [@bib35] identified a prevalence between 2% and 12% of antifolate resistant *P. falciparum* in the midguts of *Anopheles arabiensis* mosquitoes, which they discussed was very low, when in comparison, there was a high prevalence of resistance within the human population. In contrast, [@bib14] discusses that there is no discernible cost associated with maintaining resistance afforded by highly resistant triple or quadruple mutations in *P. falciparum*.

The model assumes that the female *An.* mosquito can only be infected with one strain of *P. falciparum*. In the occasion when the mosquito feeds on a human containing a mixed infection, the probability of *P. falciparum* SP-sensitive gametocytes being selected over SP-resistant gametocytes in the *An.* mosquitoes midgut is defined by $\text{P}_{\text{w}}$, and set to 0.60 (where $0 \leq \text{P}_{\text{w}} \leq 1$). This value for $\text{P}_{\text{w}}$ assigns a small cost to resistance. This assumption was made in order to simplify the model.

D2. . Transmission from humans to mosquitoes $\left( {\widetilde{Z}}_{i} \right)$ {#appsec4.2}
---------------------------------------------------------------------------------

The overall probability of gametocyte transmission from human to mosquito, for each *P. falciparum* infection $\left( i \right)$, treatment $\left( d \right)$ combination, are as follows:$${\widetilde{Z}}_{w} = \sum\limits_{d}\theta_{d}Z_{w,d} + P_{w}\sum\limits_{d}\theta_{d}Z_{wr,d}$$$${\widetilde{Z}}_{r} = \sum\limits_{d}\theta_{d}Z_{r,d} + \left( {1 - P_{w}} \right)\sum\limits_{d}\theta_{d}Z_{wr,d}$$where ${\widetilde{Z}}_{w}$ and ${\widetilde{Z}}_{r}$ denote the overall expected probability of transmission of SP-sensitive $\left( w \right)$ and SP-resistant $\left( r \right)$ gametocytes from human to mosquito, respectively; $\theta_{d}$ denotes the percentage of drug use for each treatment type, $d$ ($d = q$ for AL, $d = m$ for ful-dose SP, $d = p$ for half-dose SP, and $d = n$ for no treatment); $Z_{w,d}$ denotes the probability of SP-sensitive gametocyte transmission under each treatment, $d$; $Z_{r,d}$ denotes the probability of SP-resistant gametocyte transmission under each treatment, $d$; $Z_{wr,d}$ denotes the probability of a mixed infection gametocyte transmission under each treatment, $d$; and $P_{w}$ denotes the fitness cost (see [Appendix D1](#appsec4.1){ref-type="sec"}).

E. Mosquito parameters {#appsec5}
======================

The model parameters for the female *An.* mosquito are defined in [Table E.1](#dtbla11){ref-type="table"}, along with the parameter values used, the parameter range, and the published reference or the Appendix reference where this parameter is defined.Table E.1**Anopheles mosquito parameters**. A description of the parameters specific to female *An.* mosquitoes used in the model. For parameter values where literature values were readily available, these values, along with the range of values and references are provided. For parameters that required further manipulation from the original source, the section of the Appendices where this parameter is discussed is noted. All parameter units are in days, unless otherwise stated.Table E.1SymbolParameter descriptionValue \[range\]Reference$N_{M}$Initial ratio of mosquitoes to humans (humans = 1)0.87 \[0.5, 40\][@bib32]$\xi_{\text{Μ}}$Average life span of a female *Anopheles* mosquito in Kenya (days)8--21[@bib28], [@bib41], [@bib53], [@bib61]$\mu_{\text{Μ}}$Daily mortality rate of female mosquitoes0.0280 \[0.05, 0.5\][@bib32], [Appendix E3](#appsec5.3){ref-type="sec"}$\text{Ω}_{\text{Μ}}$Daily rate female *An.* mosquitoes reach adulthood0.0280 \[0.020, 0.27\][@bib12], [@bib28]$\text{Π}_{\text{Μ}}$Latent period of mosquitoes (days)5 \[5, 15\][@bib32]$\text{Γ}_{\text{Μ}}$Proportion of mosquitoes that are infected with P. falciparum0.40 \[0.38, 0.83\][@bib33]

E1. Movement from susceptible to exposed $\left( \beta_{M,i} \right)$ {#appsec5.1}
---------------------------------------------------------------------

The *P. falciparum* transmission rate of female *An.* mosquitoes becoming exposed to *P. falciparum* gametocytes during a blood meal is defined by$$\beta_{M,w} = c{\widetilde{Z}}_{w}$$$$\beta_{M,r} = c{\widetilde{Z}}_{r}$$where $\beta_{M,w}$ and $\beta_{M,r}$ denote the rate of female *Anopheles* mosquitoes becoming exposed to SP-sensitive $\left( w \right)$ and SP-resistant $\left( r \right)$ *P. falciparum*, respectively; $c$ denotes the daily biting rate of female *An.* mosquitoes; and ${\widetilde{Z}}_{w}$ and ${\widetilde{Z}}_{r}$ denote the overall expected probability of transmission of SP-sensitive $\left( w \right)$ and SP-resistant $\left( r \right)$ gametocytes from human to mosquito, respectively (defined in [Appendix D2](#appsec4.2){ref-type="sec"}).

E2. Movement from exposed to infected $\left( \sigma_{M} \right)$ {#appsec5.2}
-----------------------------------------------------------------

The daily rate of female *An.* mosquitoes movement from exposed to *P. falciparum* during a blood meal, to being infectious (sporozoites in salivary glands), is given by Eq. [(E2.1)](#fdE2_1){ref-type="disp-formula"}. The model assumes that infected female *An.* mosquito do not recover from an infection due to their short lifespan, as assumed in many mathematical models ([@bib32]).$$$$where $\sigma_{M}$ denotes the daily rate of female *An.* mosquitoes movement from exposed to infected; $\text{Π}_{\text{Μ}}$ denotes the latency period for female Anopheles mosquitoes; and the range is defined \[min, max\].^A^ To stabilise the model, we had to use a value less than the ranges identified in the literature.

E3. Mortality rates $\left( \mu_{M} \right)$ {#appsec5.3}
--------------------------------------------

The mortality rate of female *An.* mosquitoes is assumed equal irrespective of *P. falciparum* infection status. In order to stabilise the model, we had to use a value $\left( {\mu_{\text{Μ}} = 0.0280\ } \right)$ less than the ranges identified in the literature, a range of 0.05-0.5.

F. Sensitivity analysis {#appsec6}
=======================

The sensitivity analysis results are found in [Table F.1](#dtbla12){ref-type="table"}, where parameters that inferred a change in the total proportion of SP-resistant infections in the human population of greater than $\pm 10\%$ were considered to be significant.Table F.1**Sensitivity analysis results**. The changes in the predicted percentage of SP resistant-containing infections in humans during 2006, due to changes in parameter values. When required, values are reported to 4 d.p. ^A^ The literature parameter range is 0.020--0.27, however there were computational restrictions that only permitted a range of 0.020--0.1406 days for the sensitivity analysis.Table F.1SymbolDescriptionRange (known range or ±10%)Percentage changeBaselineMinimumMaximumMinimumMaximum$N_{H}$Human population size (initial)10.91.10.10−0.12$N_{M}$Ratio of mosquito to human population (initial)0.870.5400.32−20.55$P_{w}$Fitness cost in mosquito midgut0.60.50.75.12−6.60$\mu_{\text{Μ}}$Mortality rate of female *An.* mosquitoes0.0280.04760.1250.290.24$\text{Ω}_{\text{Μ}}$Rate female *An.* mosquitoes reach adulthood0.0280.0200.1406^A^0.26−36.20$\text{Π}_{\text{Μ}}$Latent period of *An.* mosquitoes55150.000.20$D_{M}$Kenyan 2006 malaria deaths74,97067,473824670.000.00$Y_{M}$Kenyan 2006 malarial cases8,926,0588,033,452.29818663.80.000.00$\text{Ω}_{\text{Η}}$Birth rate for humans1.1349 × 10^−4^1.0411 × 10^−4^7.8811 × 10^−4^0.00−0.11$\mu_{\text{Ι}}$Rate of malarial mortality in humans0.00110.00100.00120.000.00$\mu_{\text{Ο}}$Rate of "other" mortality in humans3.1779 × 10^−5^2.86 × 10^−5^3.50 × 10^−5^0.000.00$\text{Π}_{\text{Η}}$Latency period of asexual parasites in humans99140.00−0.04$G_{M}$Maturing of gametocytes2230.00−0.01$\eta$Delay in seeking treatment102−0.01−0.04$c$Biting rate of female *An.* mosquitoes0.4050.010.50.19−1.43$T_{w}$SP-sensitive sporozoite transmission (probability)0.20.20.50.00−86.98$T_{r}$SP-resistant sporozoite transmission (probability)0.20.20.50.0017.90$\theta_{n}$Receive no treatment (proportion, at baseline)0.20.090.20.570.00$\theta_{m}$Receiving full-dose SP monotherapy (proportion, at baseline)0.070.0630.077−0.520.54$\theta_{p}$Receiving half-dose SP monotherapy (proportion, at baseline)0.030.0270.0330.000.00$\varepsilon_{w,q}$SP-sensitive gametocyte clearance in humans treated with AL147289.20−13.61$\varepsilon_{r,q}$SP-resistant gametocyte clearance in humans treated with AL14728−15.528.65$\varepsilon_{wr,q}$Mixed infection gametocyte clearance in humans treated with AL147280.05−0.04$\varepsilon_{w,m}$SP-sensitive gametocyte clearance in humans treated with full-dose SP monotherapy25211190.52−1.56$\varepsilon_{r,m}$SP-resistant gametocyte clearance in humans treated with full-dose SP monotherapy1121128820.000.26$\varepsilon_{wr,m}$Mixed infection gametocyte clearance in humans treated with full-dose SP monotherapy112211190.010.00$\varepsilon_{w,p}$SP-sensitive gametocyte clearance in humans treated with half-dose SP monotherapy29291620.00−0.52$\varepsilon_{r,p}$SP-resistant gametocyte clearance in humans treated with half-dose SP monotherapy1121128820.000.12$\varepsilon_{wr,p}$Mixed infection gametocyte clearance in humans treated with half-dose SP monotherapy92927720.000.00$\varepsilon_{n}$Gametocyte clearance in humans not treated7530720−0.040.02$Z_{w,q}$SP-sensitive gametocyte transmission when treated with AL (probability)0.05370.01830.05375.690.00$Z_{r,q}$SP-resistant gametocyte transmission when treated with AL (probability)0.05370.01830.05375.690.00$Z_{wr,q}$Mixed infection gametocyte transmission when treated with AL (probability)0.05370.01830.05375.690.00$Z_{w,m}$SP-sensitive gametocyte transmission when treated with full-dose SP monotherapy (probability)0.0550.04950.06050.11−0.11$Z_{r,m}$SP-resistant gametocyte transmission when treated with full-dose SP monotherapy (probability)0.30.42450.49992.303.58$Z_{wr,m}$Mixed infection gametocyte transmission when treated with full-dose SP monotherapy (probability)0.310.4520.5274−0.56−0.87$Z_{w,p}$SP-sensitive gametocyte transmission when treated with half-dose SP monotherapy (probability)0.04890.04400.05380.05−0.04$Z_{r,p}$SP-resistant gametocyte transmission when treated with half-dose SP monotherapy (probability)0.01470.01250.0147−0.010.00$Z_{wr,p}$Mixed infection gametocyte transmission when treated with half-dose SP monotherapy (probability)0.19130.16390.19130.050.00$Z_{n}$Gametocyte transmission with no treatment (probability)0.20.20.50.00−4.27$\gamma_{R}$Rate of acquired immunity6.0864 × 10^−4^5.4778 × 10^−4^6.6950 × 10^−4^0.000.00$\rho$Rate of loss of acquired immunity0.00270.00240.00300.000.00

G. Model Limitations {#appsec7}
====================

There are key assumptions and limitations in the model that have an impact on the findings; these are discussed in detail below.

G1. Estimating the transmissibility and infectiousness of gametocytes {#appsec7.1}
---------------------------------------------------------------------

The transmissibility of gametocytes is estimated from the duration and density of gametocyte carriage in humans over time. A well-known property of SP is its propensity to increase gametogenesis, which in turn increases the transmission of *P. falciparum* between humans and mosquitoes ([@bib4], [@bib5], [@bib7], [@bib18]). The data to inform the asexual and gametocyte clearance rates were calculated using a combination of mice malaria data for pyrimethamine ([@bib20], [@bib22], [@bib19]), with human SP studies carried out in South Africa ([@bib4], [@bib5]) and Columbia ([@bib34]).

The mice studies looked at the effect of pyrimethamine (not in combination with sulfadoxine) on the gametocyte densities and length of infectivity over a maximum of 28 days ([@bib19], [@bib22]). In using these data, we had to assume that the estimates provided from pyrimethamine are a fair approximation of the estimates that would occur when used in combination with sulfadoxine.

We feel that the large differences in gametocyte densities and infectivity, as a result of half- and full-dose SP, are due to the experimental design of the mice studies. The pyrimethamine-sensitive infections were simulated by the injected the mice with sensitive parasites on Day One. Mixed infections had the same inoculation of pyrimethamine-sensitive parasites on Day One, followed by the introduction a small number of pyrimethamine-resistant parasites (approximately 25 parasites) on Day Five. In the pyrimethamine-resistant only studies, resistant parasites were inoculated on Day Five (25 parasites). Following this, we expect that this experimental design drives the lower SP-resistant estimates for the probability of gametocyte transmission from humans to mosquitoes $\left( Z_{r,d} \right)$ for each treatment type $\left( d \right)$, calculated in [Appendix C3.2](#appsec3.3.2){ref-type="sec"}. This limitation highlights the need for more data in this field.

The infectiousness of SP-induced gametocytes may be less than gametocytes that differentiate without the stress of SP treatment, as found with the infectiousness of SP-induced gametocytes when compared to chloroquine-induced gametocytes. However, this decrease is thought to be offset by a higher prevalence and density of gametocytes following SP treatment ([@bib3]).

For the above reasons, the accuracy of gametocyte-parameter estimates used in our model are unknown but are thought to underestimate the true value. An additional area of uncertainty in using these estimates was introduced by slight differences in experimental design between the two mice studies, when calculating estimates for a half-dose SP monotherapy treatment. These parameter estimates were calculated using data in which 50% of a full-dose of pyrimethamine ([@bib22]) and 37.5% of a full-dose of pyrimethamine ([@bib19]) was used.

G2. Transmissibility in asymptomatic infections and acquired immunity {#appsec7.2}
---------------------------------------------------------------------

Both symptomatic and asymptomatic infections harbour gametocytes ([@bib9]). The ability to transmit during asymptomatic infections are not included as they are outside of the scope of this study, as asymptomatic individuals have no reason to seek antimalarial treatment.

In a similar manner, the model does not account for the possibility of gametocyte carriage, and hence transmission to mosquitoes, in those with acquired immunity, in contrast to work carried out by [@bib24]. We deemed this outside the scope of the study, as these individuals also would not need to seek treatment. A summary of the effect of acquired immunity on gametocyte density has been carried out by [@bib11] and [@bib7]. Both papers surmise a conflict in findings by researchers; some conclude that patients with acquired immunity may be able to control asexual parasite densities better, and hence have lower gametocyte densities. However, others have shown that gametocyte densities may be at their highest in acquired immune populations. [@bib7] recommend longitudinal studies to further explore this relationship. Additionally, we do not account for any passive (maternal) immunity to malaria in infants.

G3. Patient adherence {#appsec7.3}
---------------------

Patient adherence is commonly identified as a confounding factor. In our case, SP is a single dose regimen, so we assumed perfect patient adherence. Artemether-lumefantrine in adults requires 24 tablets administered over 3 days. However, the model assumes that all AL treatment is of good quality, obtained from a reputable source and that all patients complete the treatment regime. However, there have recently been severe problems with the quality of AL in Africa ([@bib40], [@bib65]).

G4. Defining antimalarial resistance {#appsec7.4}
------------------------------------

The model assumes there is only one kind of resistance within the *P. falciparum* population, to SP. In reality, resistance has emerged to nearly all antimalarial compounds currently in use, and molecular markers associated with AL resistance have been described ([@bib40]).

When defining SP resistance within our model, tolerance and low levels of resistance were excluded, but are expected to have an impact on the spread of resistance in *P. falciparum* ([@bib52]).

G5. Mortality rates of mosquitoes {#appsec7.5}
---------------------------------

A constant mortality rate of mosquitoes was assumed, irrespective of *P. falciparum*-infection status, unlike the model produced by [@bib52]. Our model also assumed that mosquitoes could not harbour a mixed infection $\left( {wr} \right)$, and that the selection of SP-sensitive over resistant gametocytes during the bloodmeal, proceeding through to the mosquito\'s midgut and then salivary gland, occurs at $P_{w} = 0.6$. In their work, [@bib21] found that resistant parasites are suppressed in the absence of treatment (irrespective of the number of competitors in multi-clonal environments), but have a marked advantage following drug treatment. They described a pattern of transient fitness advantage but it did not appear to have an effect on the overall transmission potential. [@bib14] found no discernible cost associated with maintaining resistance afforded by highly resistant triple or quadruple mutations in *P. falciparum*. However, in a study conducted by [@bib35] a lower prevalence (2%--12%) of antifolate resistant parasites were found in the midgut\'s of *Anopheles arabiensis* mosquitoes, when compared to the high prevalence of resistance within the human population.

G6. Seasonality {#appsec7.6}
---------------

Although the temporal resolution of the parameters were daily, the model outcomes were produced as yearly measures. For this reason, seasonality was not accounted for within the model structure.
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